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Summary 
Cancer is worldwide the leading cause of death in the 21st century. Liver cancer represents the 
fourth most common cancer with hepatocellular carcinoma (HCC) being the most frequent 
primary liver cancer. HCC is the second most common cause of cancer-related deaths with a 5-
year survival rate below 12% in the US. These sobering numbers illustrate the need for bio-
medical research to identify novel target structures and to develop respective therapeutic 
strategies. The evolutionarily conserved Hippo signaling pathway is frequently deregulated in 
human hepatocarcinogenesis. Indeed, overexpression of the transcriptional co-activators yes-
associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) is 
associated with pro-proliferative and anti-apoptotic effects in liver tumor cells. However, among 
the identified direct YAP/TAZ target genes, no functional groups or protein families have been 
described, which facilitate the biological properties of YAP and TAZ in HCC cells. Since these 
groups may represent relevant molecular hubs that mediate the tumor-supporting properties of 
the Hippo pathway, this study aimed to define YAP/TAZ-regulated protein families, which may 
represent promising therapeutic target structures.  
Based on comprehensive transcriptome analysis after siRNA-mediated inhibition of YAP and TAZ 
in HCC cells, the minichromosome maintenance (MCM) protein family, which is crucial for DNA 
replication, and members of the polycomb repressive complex 2 (PRC2), which inserts epigenetic 
repression marks (trimethylation of histone H3; H3K27me3), were identified as YAP and/or TAZ 
target genes. For the MCM family members (MCM2-7), different molecular approaches 
confirmed the direct transcriptional regulation via YAP/TAZ and the transcription factor TEA 
domain transcription factor 4 (TEAD4) in independent liver cancer lines. In contrast, the PRC2 
components Enhancer Of Zeste 2 (EZH2) and Suppressor Of Zeste 12 Protein Homolog (SUZ12) 
were predominantly regulated by YAP and TEAD4. Functionally, RNAi-mediated MCM reduction 
as well as YAP and TAZ perturbations decreased cell proliferation in vitro. Additionally, YAP 
induces the expression of PRC2 components and their epigenetic mark H3K27me3 in vitro, 
leading to the repression of target gene transcription. In a YAP-dependent HCC mouse model 
(inducible expression of constitutively active YAPS127A)) a clear positive association between YAP 
overexpression and especially abundance of MCM family members confirmed the in vitro 
results. Statistical correlations between tumor progression, YAP expression and MCM2-7, EZH2, 
and SUZ12 abundance in primary patient tissues supported the hypothesis that both protein 
groups are cooperatively induced by YAP and TEAD4 in human HCC.  
Together, these results illustrate that the Hippo pathway contributes to tumor progression via 
the regulation of protein groups that induce biological functions. The transcriptional regulation 
of MCM helicase by the Hippo pathway introduces a promising surrogate marker for YAP driven 
proliferation. Furthermore, YAP induced transcription of PRC2 members illustrates a new 
Summary 
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possibility of YAP mediated gene silencing and offers a novel approach to understand oncogenic 
Hippo/YAP feedback loops. Interestingly, both YAP and TAZ are important for the regulation of 
all MCM family members, while data for PRC2 constituents point to a predominant role of YAP. 
This differential dependency of target genes might represent a molecular mechanism of how 
the Hippo pathway regulates specific biological processes, as epigenetic changes and 
replication. This is of special importance since direct perturbation of the Hippo/YAP/TAZ-axis 
could also inhibit pro-regenerative properties (e.g. proliferation), which might be of relevance 
for patients with chronically damaged livers. Thus, targeting these important downstream hubs 
could represent one strategy to selectively impair YAP and/or TAZ-dependent HCC cell 
functionality while saving physiological hepatocellular proliferation in regenerative livers, which 
could maintain residual liver function. Still, further studies are needed to test if MCM proteins 
and PRC2 are suitable points-of-interference in HCC patients with YAP and/or TAZ activation.  
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Zusammenfassung 
Weltweit sind Krebserkrankungen die häufigste Todesursache im 21. Jahrhundert. Die 
vierthäufigste Krebsart ist Leberkrebs, wobei das Hepatozelluläre Karzinom (hepatocellular 
carcinoma; HCC) der häufigste primäre Leberkrebs ist. Außerdem ist das HCC weltweit die 
zweithäufigste krebsbedingte Todesursache mit einer 5-Jahres-Überlebensrate von unter 12 % 
in den USA. Diese ernüchternden Zahlen verdeutlichen die Notwendigkeit neue therapeutische 
Strategien zu entwickeln. Hierzu müssen zunächst relevante Zielstrukturen identifiziert werden. 
In der humanen Hepatokarzinogenese liegt der evolutionär konservierte Hippo-Signalweg häufig 
dereguliert vor, wobei die Überexpression der transkriptionellen Co-Aktivatoren yes-associated 
protein (YAP) und Transcriptional Co-Activator With PDZ-Binding Motif (TAZ) mit pro-
proliferativen und anti-apoptotischen Effekten in Lebertumorzellen einhergehen. Bisher wurden 
keine funktionellen Gruppen oder Proteinfamilien unter den identifizierten direkten Zielgenen 
beschrieben, die die biologischen Eigenschaften von YAP und TAZ in HCC-Zellen vermitteln. Da 
diese Gruppen relevante molekulare Knotenpunkte bei der Vermittlung tumorunterstützenden 
Eigenschaften des Hippo-Signalwegs darstellen können, war es das Ziel dieser Studie 
vielversprechende therapeutische Zielstrukturen unter den YAP/TAZ-regulierten Proteinfamilien 
zu definieren.  
Basierend auf einer umfassenden Transkriptomanalyse, nach siRNA-vermittelter Reduktion von 
YAP und TAZ in HCC-Zellen, wurden zwei Proteinfamilien als YAP- und/oder TAZ-Zielgene 
identifiziert. Der für die DNA-Replikation relevante minichromosome maintenance (MCM)- 
Komplex wurde durch YAP, TAZ und den Transkriptionsfaktor TEA Domain Transkriptionsfaktor 4 
(TEAD4) transkriptionell reguliert, was durch verschiedene molekularbiologische Methoden in 
unabhängigen HCC-Zelllinien bestätigt wurde. Weiterhin wurden die Mitglieder des polycomb 
repressive complex 2 (PRC2), der epigenetische Repressionsmarkierungen (Trimethylierung des 
Histons H3; H3K27me3) einfügt, überwiegend durch YAP und TEAD4 reguliert 
Funktionell führte die RNAi-vermittelte MCM-Reduktion, sowie die YAP- und TAZ-Reduktion, zu 
einer verringerten Zellproliferation in vitro. Darüber hinaus induziert YAP die Expression der 
PRC2-induzierten epigenetischen Markierung H3K27me3 in vitro und unterdrückt so potentiell 
die Transkription der Zielgene. In einem YAP-abhängigen HCC-Mausmodell (induzierbare 
Expression von konstitutiv aktivem YAPS127A) bestätigte sich eine klare Assoziation zwischen YAP-
Überexpression und vor allem einer erhöhten Konzentration an MCM-Familienmitgliedern. 
Statistische Korrelationen zwischen dem Tumorwachstum, der YAP-Expression und der 
Überexpression von MCM2-7 und den PRC2 Komponenten Enhancer Of Zeste 2 (EZH2) und 
Suppressor Of Zeste 12 Protein Homolog (SUZ12) unterstützten die Hypothese, dass beide 
Proteingruppen im humanen HCC durch YAP induziert werden. 
Zusammenfassung 
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Gemeinsam zeigen diese Ergebnisse, dass der Hippo-Signalweg durch die Regulation ganzer 
Proteinfamilien zur Tumorprogression beiträgt. Die transkriptionelle Regulation der MCM-
Helikase durch den Hippo-Signalweg stellt einen vielversprechenden Marker für die YAP-
abhängige Proliferation dar. Darüber hinaus ist die YAP-induzierte Transkription von PRC2-
Komponenten ein neuer Modus der YAP-vermittelten Genrepression und bietet einen Ansatz 
zur Untersuchung potentieller onkogener Hippo/YAP-Feedback-Mechanismen. 
Interessanterweise sind sowohl YAP als auch TAZ für die Regulierung aller MCM-
Familienmitglieder wichtig, während Daten für die PRC2-Komponenten auf eine dominante 
Rolle von YAP hinweisen. Diese unterschiedliche Abhängigkeit von Zielgenen könnte einen 
molekularen Mechanismus des Hippo-Signalwegs darstellen um spezifische biologische 
Eigenschaften in verschiedenen Zellphasen zu regulieren. Dieses Wissen ist von besonderer 
Bedeutung, da eine direkte Perturbation der Hippo/YAP/TAZ-Signalachse auch regenerative 
Eigenschaften beeinflusst, welche essentiell für Patienten mit chronisch geschädigten Lebern 
sein können. Somit könnte die Fokussierung auf diese wichtigen nachgelagerten Knotenpunkte 
eine mögliche Strategie darstellen, um selektiv die YAP- und/oder TAZ-abhängige onkogene 
HCC-Zellfunktionalität zu beeinträchtigen und gleichzeitig die physiologische hepatozelluläre 
Proliferation in regenerativen Lebern zu erhalten. Dennoch sind weitere Studien erforderlich, 
um zu testen, ob MCM-Proteine und PRC2 geeignete therapeutische Angriffspunkte bei HCC-
Patienten mit YAP- und/oder TAZ-Aktivierung sind. 
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1 Introduction 
1.1 Liver and Liver Cancer  
1.1.1 Anatomy and Physiology of the Liver 
The liver is the major metabolic organ of the human body, located in the upper right abdomen 
and accounts for about 2% of the body weight. It has a unique blood supply with 20-25% of 
oxygenated blood afflux being provided by the hepatic artery (1). The remaining 75-80% of the 
blood supply is provided by the hepatic portal vein, perfusing the liver with nutrient-rich blood 
directly from the gastrointestinal tract. Microscopically, the liver is formed by small, hexagonal 
lobules of 1-2 mm in diameter (2). The junctions of the lobules comprise periportal fields, which 
contain vessels of the portal vein, the hepatic artery, and the biliary tract. Due to this structure 
and the permanent contact with oxygenated and nutrient-rich blood, the liver is central for 
carbohydrate, protein, and lipid metabolism, substance storage (e.g. glycogen and vitamin A) 
and synthesis (e.g. amino acids, coagulation factors). Newly synthesized molecules are 
transported through the central vein located in the center of each lobule to the vena hepatica 
into the vena cava inferior, thereby efficiently distributed in the body (1). 
In addition, the liver is the main detoxifying organ responsible for the elimination of toxic 
metabolites along with bile salts via the bile duct and the gallbladder (3). Metabolic functions 
are mainly mediated by hepatocytes, which account for about 60% of all liver cells. These cells 
are frequently binucleated, parenchymal cells and play a key role in carbohydrate, lipoprotein, 
and cholesterol metabolism (2). Nonparenchymal cells include capillary endothelial cells (CECs), 
liver sinusoidal endothelial cells (LSECs), Kupffer cells, and stellate cells. CECs and LSECs 
separate hepatocytes from the bloodstream and facilitate the so-called porto-central blood 
flow. Kupffer cells represent liver-specific macrophages and localize in the sinusoids acting as 
central sensors for immunogenic substances and regulators of immune responses. Lastly, 
hepatic stellate cells are located in the Space of Disse between hepatocytes and LSECs, where 
they produce collagen and extracellular matrix (ECM) material.  
1.1.2 Pathophysiology of Liver Cancer 
Epidemiology, Risk Factors, and Pathogenesis  
Worldwide, cancer is the leading cause of death in the 21st century with estimated 18.1 million 
new cases and 9.6 million deaths in 2018. In Europe harboring only 9% of the global population, 
23% of all new cancer cases were diagnosed (4). Primary liver cancer represents the fourth most 
common cancer and the second most common cause of cancer-related deaths worldwide with 
over 780,000 estimated deaths per year (4). The gender difference in liver cancer susceptibility 
is comparable to other tumor entities with a 2-fold higher incidence in men than in women (4). 
Introduction 
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The most frequent primary liver cancer diagnosis with 75-85% of all cases is hepatocellular 
carcinoma (HCC), developing in most cases from hepatocytes, while only 10-15% represent 
intrahepatic cholangiocarcinoma mainly arising from cholangiocytes of the biliary tree (4). 
About 90% of all HCCs develop on the basis of fibrosis and cirrhosis due to chronic liver damage 
(5). The reasons for this permanent insult are diverse and include infections with viruses, 
alcohol abuse, hereditary diseases, uptake of mycotoxins, non-alcoholic steatohepatitis (NASH), 
obesity and type 2 diabetes.  
Chronic hepatitis upon hepatitis B (HBV) and C virus (HCV) infection accounts for 50% and 30% 
of all global HCC cases, respectively, most of them located in high-risk countries in Asia and 
Africa (5). The developement of HBV vaccines reduced infection rates upon mass vaccination in 
Asia followed by reduced HCC rates (6). However, a HCV vaccine does not exist, but novel Food 
and Drug Administration (FDA)-approved strategies for the treatment of patients with chronic 
HCV infections have been developed since 2013. These modern 'direct antiviral agents' target 
several aspects of virus biology including its replication (e.g. by sofosbuvir) and the activity of 
viral proteins such as polyprotein;protein F (POLY) (e.g. by ledipasvir). Clinical studies showed a 
90% response rate, which led to the expectation that this multi-modal drug cocktail will reduce 
the incidence of chronic HCV hepatitis and HCV-associated HCC development in the future (7). 
In Western countries, alcoholic steatohepatitis (ASH) and non-alcoholic fatty liver disease 
(NAFLD) followed by NASH are the most frequent underlying diseases for HCC development 
with increasing incidence (8). In addition, there are several other risk factors leading to cirrhosis 
and HCC such as type 2 diabetes and obesity (Figure 1), which increase the risk to develop HCC 
about 1.8 to 4-fold and 1.5 to 4-fold (9). 
 
Figure 1: Schematic illustration of hepatocarcinogenesis. 
The scheme illustrates the progression from risk factor exposure over chronic liver disease and cirrhosis to HCC development. 
The arrows indicate the percentage of patients progressing to the next pathological stage over time (10). 
Pathogenesis of liver cancer is a multi-step and long-lasting process starting with prolonged 
exposure to risk factors, which leads to chronic diseases such as chronic virus hepatitis, ASH or 
NAFLD/NASH. Over months and years, continuous cycles of liver damage (hepatocellular 
damage and apoptosis) and regeneration (hepatocellular proliferation) could eventually result 
in cirrhosis (11). It is characterized by the excess formation of fibrous connective tissue (fibrosis) 
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separating regenerating nodules and thereby perturbating blood flow and normal liver function. 
HCCs arising on the basis of cirrhosis are characterized by chronic inflammation, one of the 
hallmarks of cancer (12). During inflammation, activated stellate and infiltrating immune cells 
produce pro-inflammatory cytokines, which could enhance hepatocellular proliferation. This 
leads to replicative stress, shortening of telomeres and genomic instability causing precancerous 
lesions and eventually tumor formation (12). It is assumed that replicative stress, usually 
defined as replication fork stalling induced by oncogenes or dysfunction of DNA-damage 
checkpoint, interferes with regulatory pathways, which control the timing and progression of 
the replication machinery (13). However, the exact mechanisms are not fully understood yet. 
Permanent cell division is the basis for an accumulation of genetic mutations and chromosomal 
alterations, promoting the outgrowth of hepatocytes with abnormal proliferating capacities and 
resulting in dysplastic nodules as well as malignant transformation (12). 
Treatment Options and Prognosis 
Liver cancer presents as the second leading cause of cancer-related deaths worldwide with 
mortality to incidence ratio of 0.95 (14). The 5-year overall survival rate for a patient diagnosed 
with HCC in the US is below 12%, emphasizing the need for improvement in current therapy (5). 
The established treatment options for HCC can be grouped into three approaches: surgical 
intervention, percutaneous treatment, and pharmaceutical drugs. The surgical approach 
includes tumor resection and liver transplantation, which is limited by organ availability and 
severity of the patient's liver damage. It is so far the only curative approach, increasing the 5-
year survival rate of early-stage HCC patients to 75% (5). The second treatment option can 
reduce tumor load by percutaneous interventions, which includes ethanol injection, 
radiofrequency or thermal ablation and transarterial interventions (embolization, 
chemoperfusion, or chemoembolization). Until now, systemic pharmaceutical approaches for 
the first-line treatment of HCC comprises of two FDA-approved therapies (sorafenib and 
lenvatinib). The SHARP trial illustrated that the first established multikinase inhibitor sorafenib 
prolonged the average survival of HCC patients by about 3 months (10.7 months with drug vs. 
7.7 months with placebo) (15). A decade later the REFLECT trial demonstrated that the tyrosine-
kinase inhibitor lenvatinib showed comparable effects on median overall survival (13.6 months 
with lenvatinib vs. 12.3 months with sorafenib) (16). Recently other systemic therapies have 
been FDA-approved, as second-line treatment in patients with disease progression after 
sorafenib treatment. Besides the multi-kinase inhibitor regorafenib (15) and the tyrosine-kinase 
inhibitor cabozantinib (17), which perturbates c-MET, VEGFR1/2/3, FLT3, and c-KIT, the 
programmed cell death protein-1 (PD-1) immune checkpoint inhibitor nivolumab (18) is the first 
attempt targeting viral related HCC. However, all these therapies only moderately improve the 
overall survival of HCC patients, which illustrates the need to develop alternative therapeutic 
approaches. 
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1.1.3 Molecular Carcinogenesis of HCC 
Molecular Classification 
HCCs are characterized by a high genetic and phenotypic heterogeneity, partly due to a diverse 
etiology, late diagnosis, and complexity of hepatocyte function (19). In order to understand the 
underlying mechanisms in distinct HCC subgroups and to identify subgroups of patients who 
may benefit from targeted therapies, intense research was done on the molecular classification 
of HCCs. During tumorigenesis, genetic and epigenetic alterations are frequently observed, 
which results in deregulated expression of oncogenes and tumor suppressor genes (19). The 
most frequent mutations found in HCCs are activating mutations in the gene promoter of the 
telomerase reverse transcriptase (TERT) enzyme (20). In about 30-60% HCC cases, these 
mutations lead to the re-expression of TERT providing cells with indefinite proliferative capacity 
by circumventing DNA damage checkpoint-induced senescence. 
A well-accepted scheme to classify HCCs was published by Boyault et al. in 2007, using a 16 
gene-signature to cluster HCCs with distinct molecular and functional features (21). A further 
characterization was performed in 2017 by Calderaro et al., investigating 343 HCC samples by 
pathological assessment, immunohistochemistry, gene expression profiling, and DNA 
sequencing (22). Based on these data, HCCs can be clustered in even more subgroups (G1-G6) 
with molecular, biological and clinical characteristics (Figure 2). 
 
Figure 2: Molecular classification of HCC.  
Scheme modified after Calderaro et al. classifying HCCs groups (22). 
The G1/G2/G3-groups are characterized by high cell proliferation, chromosomal instability, poor 
tumor differentiation, and the presence of p53 mutations. In 18-50% of all HCC cases, gene 
mutations in the p53 gene (TP53) were found, prohibiting the induction of cell cycle arrest and 
apoptosis upon DNA damage (20). Similar effects can be observed upon upregulation of the p53 
inhibitor MDM2 or gene silencing of the tumor suppressor p16/CDKN2/INK4A (23). HCCs 
grouped G4/G5/G6 show better differentiation, do not exhibit p53 mutations and show less cell 
proliferation as well as chromosomal stability. 
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In detail, G1 is characterized by high serum AFP levels, female gender and integration of HBV 
DNA in low copy number. HCCs clustered in that group showed activation of MAP kinase and 
PI3K/AKT pathway. Mutated RAS family members have been rarely described in HCC, but recent 
studies showed copy number gains and overexpression of key genes as B-Raf and H-ras (24). In 
addition, dysregulation of PI3K signaling leads to permanently activated Akt, which is linked to 
deregulation of cell growth and differentiation as well as poor prognosis and sorafenib 
resistance (25). Since this pathway is upregulated in 40-50% of all HCC cases, drugs targeting the 
PI3K/Akt/mTOR pathway are currently tested in phase I clinical trials (25). G2 tumors show a 
high copy number of integrated HBV DNA and also PI3K/Akt/mTOR pathway activation. 
The G3 subgroup has the worst prognosis due to the association with macrotrabecular-massive 
HCC-subtype and enhanced vascular invasion. Tumor recurrence and poor prognosis coincide 
with increased circulating Vascular Endothelial Growth Factor (VEGF) levels, which induce 
physiological and pathological angiogenesis. During HCC development pathological angiogenesis 
results in abnormal vascular invasion providing a nutrition rich and hypoxic microenvironment 
and therefore facilitating therapy resistance, cell proliferation, and tumor growth (26). Recent 
data indicate that dysregulation of the so-called Hippo pathway, which is associated with 
chromosomal instability and worse clinical outcome, is especially detectable in G1 and G3 (27). 
G4 is a heterogeneous subgroup of tumors including inflammatory and steohepatitic subtype, 
arising on the basis of fibrotic or cirrhotic livers. This process is associated with elevated 
infiltration of immune cells and activation of the nuclear factor kappa B (NF-κB) signaling 
pathway in tumor cells, which induces proliferation and cell cycle progression via activation of 
cyclin D1 (28). G5 and G6 clustered HCCs show a high rate of activating β-catenin mutations, the 
third most frequent HCC driver mutation, which leads to Wingless-Type MMTV Integration Site 
(Wnt) pathway activation. The Wnt-signaling pathway plays an important role in cell 
differentiation during embryogenesis, cell proliferation, and tumorigenesis. Wnt activation 
results in nuclear β-catenin accumulation, which is associated with the acquirement of stemness 
characteristics, high proliferation rate and immortality of HCC cells (11). 
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1.2 Hippo Pathway 
1.2.1 Structure and Regulation of the Hippo Pathway 
Hippo Pathway in Drosophila melanogaster and Mammals 
The Hippo signaling pathway is an evolutionarily highly conserved signaling pathway and has key 
functions in the regulation of cell proliferation and tissue homeostasis, as first demonstrated in 
Drosophila melanogaster and subsequently in mammals. The first member described in this 
pathway was the kinase warts (Wts) in 1995, which was identified in a genetic mosaic screen for 
regulators of tissue growth in Drosophila melanogaster (29). Mutational inactivation of Wts led 
to hyperproliferation and overgrowth e.g. of the compound eye, the wing blades, and the wing 
discs (29). Similar phenotypes were observed for mutations in other pathway constituents such 
as hippo (Hpo), salvador (Sav) and mob as tumor suppressor (Mats) (30-32). The discovery of the 
transcriptional co-activator yorkie (Yki) as a negatively regulated downstream effector of the 
Hippo pathway in 2005 illustrated how the pathway affects the transcriptional machinery (33). 
Indeed, Yki overexpression and its subsequent interaction with the transcription factor 
scalloped (Sd) showed the same phenotype as observed for Hippo pathway component 
inactivation such as uncontrolled tissue overgrowth (34).  
 
 
 
Figure 3: Scheme of the mammalian Hippo pathway. 
Activation of the Hippo pathway is characterized by sequential 
phosphorylation of Mst1/2 and Lats1/2, which leads to phosphorylation of 
YAP/TAZ and their nuclear exclusion. In contrast, inactivation of the Hippo 
pathway is associated with the inactive non-phosphorylated form of Mst1/2, 
Lats1/2, and successive de-phosphorylation of YAP and TAZ. Hypo-
phosphorylated YAP and TAZ translocate into the nucleus, where they bind 
to transcription factors (e.g. TEAD family members) and initiate the 
transcription of pro-proliferative and anti-apoptotic target genes. 
 
In mammals, the core kinase cassette of the Hippo pathway is composed of two serine-
threonine kinases mammalian Ste20-like kinases 1 and 2 (MST1/2; Hippo homologs) and large 
tumor suppressor kinases 1 and 2 (LATS1/2; Warts homologs), which physically interact with the 
scaffolding proteins Salvador family WW domain-containing protein 1 (SAV1; Salvador homolog) 
and Mps one binder kinase activator-like 1A and 1B (MOB1; Mats homologs), respectively (35). 
Following Hippo pathway activation (Figure 3), MST1/2 facilitate the phosphorylation of SAV1 
and MOB1 leading to the recruitment and phosphorylation of LATS1/2. Consequently, the 
activated kinases LATS1/2 phosphorylate the mammalian orthologues of Yki, Yes-associated 
protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ; also called WWTR1; 
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paralogue of YAP), at 5 and 4 serine/threonine sites, respectively (36). Especially, 
phosphorylation at S127 in YAP and S89 in TAZ create 14-3-3 protein-specific binding sites, 
which prevent YAP and TAZ from being translocated into the nucleus. Additionally, 
polyphosphorylation is associated with polyubiquitination and proteasomal degradation of both 
factors, as was reported for S381 (YAP) and S311 (TAZ) phosphorylation (30).  
Vice versa, inactivation of the pathway is associated with the hypophosphorylation of YAP/TAZ 
as well as their nuclear translocation and induction of transcription. Since YAP and TAZ lack 
specific DNA binding sites, the interaction with transcription factors is needed to facilitate their 
biological responses. So far, a couple of YAP/TAZ-interacting transcription factors have been 
described. However, most target genes are regulated by TEA domain transcription factor (TEAD; 
Scalloped homologs) family members, which makes the YAP/TEAD interaction an interesting 
target structure for the development of anti-cancer drugs (34, 37). Beside the well-
characterized target genes, connective tissue growth factor (CTGF) and cysteine-rich angiogenic 
inducer 61 (CYR61), additional downstream effectors involved in proliferation and cell growth 
have been described, including forkhead box M1 (FOXM1), cyclin B1 (CCNB1) and 
minichromosome maintenance complex component (MCM) 2 (38). But, how exactly YAP and TAZ 
regulate complex processes such as proliferation and organ growth remains poorly understood. 
In addition, it is not sufficiently elucidated whether the Hippo/YAP/TAZ signaling pathway 
directly mitosis-related proteins.  
Regulation of Hippo Pathway Activity  
The Hippo pathway and the subcellular localization of YAP/TAZ are regulated by various cell-
autonomous and external stimuli. Interestingly, no distinct ligand/receptor combination has 
been described that affect the Hippo/YAP/TAZ axis. Instead, cell-cell contacts, interaction with 
the ECM and cell polarity represent key regulators of this pathway (Figure 4). In this context, cell 
contact inhibition has been linked to Hippo pathway activity in cell culture models, where 
nuclear exclusion of YAP/TAZ and Hippo core kinase cassette activation was gradually observed 
with increasing cell density (39). Cell polarity and cell contact proteins belong to the most 
potent activators of the Hippo pathway that stimulate LATS1/2 phosphorylation, as well as 
binding of YAP and TAZ, thereby preventing nuclear translocation. Many upstream regulators of 
the Hippo pathway are part of adherence junctions (e.g. E-cadherin) and tight junctions (e.g. 
claudins). Proteins involved in adherence and tight junctions such as protein tyrosine 
phosphatase non-receptors (PTPN), α-catenin and Angiomotin (AMOT), circumvent the Hippo 
core kinase cassette by sequestrating YAP/TAZ and thereby repressing their transcriptional 
activity (35). Moreover, the known tumor suppressor neurofibromatosis 2 (NF2) links 
cytoskeletal components with membrane proteins and affects Hippo pathway activity. In this 
case, NF2 associates with the cytoplasmic phosphoprotein Kibra activating the Hippo core 
kinase cassette by recruiting LATS1/2 to the plasma membrane (40). The cell density-based 
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activity of YAP/TAZ is not only regulated by junctional proteins, but also by changes in ECM 
composition. It was reported that Rho-GTPase signaling affects YAP/TAZ localization by 
combining cell density effects with G-protein coupled receptors (GPCR) signaling, upon growth 
factor or hormone activation (41).  
 
Figure 4: Complex upstream regulation of the Hippo pathway. 
Several intrinsic and extrinsic signals regulate the subcellular localization of YAP and TAZ. Cell polarity complexes, e.g. tight 
junctions, adherence junctions, and Crumbs complex, directly bind YAP/TAZ to the cell membrane. Extracellular matrix (ECM) 
composition and GPCR signaling transmit extracellular signals via RhoGTPase or Hippo signaling. 
1.2.2 The Role of the Hippo Pathway in Cell Proliferation  
The functional relevance of the Hippo pathway in embryonic development has been widely 
studied using different mouse models. It has been shown that mice with systemic TAZ knockout 
are viable but suffer from diseases resembling human polycystic kidneys and pulmonary 
emphysema (42). In contrast, systemic YAP knockdown results in embryonic lethality with signs 
of developmental perturbations as shortened body axis and failure of chorioallantoic fusion 
(43). These results suggest that YAP and TAZ are not redundant but have independent functions 
in embryonic development. Interestingly, the homozygous knockouts of upstream Hippo 
pathway components such as Lats2 (44), Mob1 (45), Sav1 (46), and Mst1/2 (47) also cause an 
embryonic lethality. In addition, these data illustrate that organ- or even cell-type-specific 
mouse models are required for a detailed analysis of Hippo/YAP/TAZ pathway constituents 
under different conditions.  
Consistently with in vitro data, the liver-specific and inducible knockout of MST1/2 in newborns 
led to increased proliferation and tissue overgrowth, which resulted in tumor formation after 6 
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months (48). Interestingly, these mice showed increased nuclear YAP accumulation due to 
reduced phosphorylation and elevated protein levels. In contrast, reduced phosphorylation and 
overall protein levels had no effects on the nuclear presence of TAZ (49). This suggests that YAP 
plays a more important role in the induction of proliferation in the liver than TAZ. The relevance 
of YAP on mitosis has been confirmed using inducible and liver-specific overexpression of 
S127A-mutated YAP (YAPS127A), which cannot be phosphorylated and therefore efficiently 
translocates into the nucleus. Mutant hyperactive YAP expression in murine hepatocytes 
induced proliferation of cells with a so-called oval cell phenotype and led to increased cell 
number and hepatomegaly (4-5-fold increase of liver size) (50). Withdrawal of YAPS127A reversed 
the phenotype by reducing cell number suggesting the activation of intrinsic control 
mechanisms (50). Interestingly, the effects of Hippo deregulation on organ size had only slight 
effects on other organs in mice (48). Furthermore, YAP also controls liver growth under 
regenerative conditions. Following partial hepatectomy (PHx), a living organ donation in humans 
or a mouse model, organ size is restored within 8-15 days in humans and 5-7 days in mice, by 
increased proliferation of differentiated liver cells (51). Indeed, PHx led to an induction of YAP 
activation and decreased MST1/2 and LATS1/2 phosphorylation, which returned to basal levels 
as soon as the livers regained its original size (52). These results illustrate the relevance of a 
functionally intact Hippo/YAP pathway signaling in embryogenesis and under regenerative 
conditions in mammalian livers. 
The Hippo/YAP Pathway in Cancer/HCC 
A hallmark of cancer is the capability of cells to evade growth suppression, which results in 
unlimited proliferation (53). Due to the central role of the Hippo/YAP pathway in the regulation 
of cell proliferation, its oncogenic and tumor-supporting properties have been discussed for 
many different cell-types and organs. 
Dysregulation of several Hippo pathway components has been observed in different tumor 
entities. For example, down-regulation of LATS1/2 and MST1/2 was found in lymphoblastic 
leukemia (54), HCC (49) and soft tissue sarcomas (55). Reduced expression of the scaffolding 
protein MOB1 has been reported in nonsmall cell lung cancer (56) and colorectal cancer (57), 
which correlated with worse clinical outcome. Interestingly, genomic mutations of Hippo 
pathway components, like genomic deletions or loss-of-function mutations in NF2, LATS1/2, and 
MST1/2, are rare and have only been observed in meningiomas, schwannomas, and 
mesotheliomas (58). In contrast, epigenetic modifications affecting Hippo pathway constituents 
occur already in pre-cancerous lesions and lead to altered gene expression in different tumor 
types. Exemplarily, the hypermethylation of CpG-islands in MST1/2 and LATS1/2 promoter 
regions resulted in reduced gene expression in human soft tissue sarcomas (55) and aggressive 
breast cancers (59).  
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In contrast to the frequent mutations within the Hippo core-cassette, epigenetic or genetic 
changes of the pathway effectors YAP and TAZ are rare. Amplifications of the YAP locus at 
11q22 are hypothesized to be driving mutations, which have been identified in few esophageal 
cancers and HCC (60). However, alterations in the phosphorylation pattern and subcellular 
localization of YAP and TAZ are observed more frequently among different tumor types. High 
YAP levels were reported in multiple tumor entities, including ovarian, lung, prostate cancer, 
and HCC (61, 62). Furthermore, reduced YAP phosphorylation was ascertained in 70% of all 
human HCCs and correlated with reduced MST1/2 activity (49). In contrast, nuclear TAZ 
accumulation was only observed in 20% of analyzed breast cancer patients (63). This either 
reflects minor biological relevance of TAZ or a scientific focus on YAP-mediated downstream 
signaling. Nevertheless, YAP and TAZ have been discussed to be involved in the regulation of 
stemness and evading apoptosis. For example, TAZ protein levels were elevated in isolated 
cancer stem cells (CSC) (64), which was corroborated by enforced TAZ overexpression in oral 
cancer cells conferring CSC-like properties (65). Knock-down of YAP in different human cancer 
cell lines reduced the proliferative capacities of tumor cells and increased DNA damage-induced 
apoptosis (66). 
The dysregulation of Hippo signaling and overexpression of YAP or TAZ have been frequently 
described in the context of tumorigenesis, especially in HCCs (49) and precancerous lesions such 
as NASH livers (67). In order to study the mechanisms involved in Hippo pathway induced 
hepatocarcinogenesis different mouse models have been introduced. In 2007, the first 
publication of a liver-specific mouse model illustrated that long-term elevated YAP expression 
led to liver tumor formation (30). Short-term exposure of these ApoE/rtTA-YAP mice to Dox 
increased the liver size constantly but was reversible upon doxycycline withdrawal (30). 
Targeting the Hippo pathway, a conditional knockout mouse was generated specifically 
inactivating the gene for WW45 in the liver, WW45flox/floxAlbumin-Cre mice (68). Within the first 
three months, these mice showed only slight changes in development without a detectable 
malfunction of the liver. Upon aging, the transgenic mice showed expansion of oval cells and 
nuclear YAP accumulation in the liver. Hepatoma formation in these transgenic mice was 
detected at the age of 12 months, illustrating that that the Hippo pathway can limit the 
hyperexpansion of progenitor cells (68). 
To confirm the relevance of the Hippo core kinases in HCC different MST knockout mice were 
generated. Homozygous liver knockout of MST1 and MST2 was lethal, whereas knockout of 
either MST1 or MST2 had no effects, demonstrating the redundancy of these kinases (49). 
Consistently, mice with only one wildtype allele of MST1 or MST2, engineered by homozygous 
knockout of MST1 and heterozygous knockout of MST2 or vice versa, were viable and fertile. 
Interestingly, these mice eventually developed highly aggressive HCCs with total MST1/2 
knockout (49). The intact Hippo pathway in the surrounding liver demonstrated, that 
spontaneous MST1/2 deletion, equivalent to Hippo pathway inactivation, can be sufficient to 
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induce HCC formation. 
However, the involvement of deregulated Hippo pathway components in human HCC and Hippo 
pathway downstream effectors responsible for tumor formation are largely unknown. 
Additionally, the mechanism of YAP and TAZ-induced proliferation and hepatocarcinogenesis in 
murine and human HCC needs to be further elucidated.  
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2 Objectives 
Worldwide, HCC is the second most common cause of cancer-related death. However, systemic 
curative options are missing, yet. The Hippo pathway and its downstream effectors YAP and TAZ 
are critically involved in the initiation and progression of liver cancer and may therefore 
represent promising therapeutic target structures. Due to the fact that the Hippo/YAP/TAZ 
signaling axis is also essential for regenerative processes, direct targeting of YAP and/or TAZ 
may cause unwanted side effects, especially under conditions of chronic liver damage. For this 
reason, the identification of functionally relevant YAP/TAZ effector mechanisms is crucial to 
finding alternative and druggable target structures. These factors or protein families could be 
used for the development of anti-cancer therapies and minimize side effects under regenerative 
conditions.  
Therefore, the aims of this thesis were: 
- Identification of functional protein groups, which are regulated by YAP and/or TAZ. 
- Description of the molecular YAP and/or TAZ-dependent mechanisms that regulate these 
functional groups. 
- Functional characterization and comparison of identified family members.  
- Verification of downstream effectors in a YAP-dependent and liver-specific HCC model. 
- Confirmation of gene regulation and YAP/TAZ target genes in cohorts of HCC patients.   
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3 Materials 
3.1 Antibodies 
Table 1: Primary antibodies. 
Antigen 
(clone) 
Species Application Dilution 
Blocking 
agent 
Secondary 
dilution 
Company 
Actin 
(C4) 
mouse WB 1:10,000 BSA 1:20,000 
MP Biomedicals 
Germany GmbH, 
Eschwege, Germany 
EZH2 
(D2C9) XP® 
rabbit 
IHC 1:50 - - Cell Signaling 
Technology Europe, 
B.V., Frankfurt am 
Main, Germany 
WB 1:500 BSA 1:20,000 
GAPDH chicken WB 1:10,000 BSA 1:20,000 
Merck Millipore, 
Darmstadt, Germany 
Histone H3 
(1B1B2) 
mouse WB 1:800 BSA 1:20,000 Cell Signaling 
Ki67 mouse IHC 1:400 - - 
Dako - Agilent 
Technologies Sales & 
Services GmbH & 
Co. KG, Hamburg, 
Germany 
MCM2 (D7G11) 
XP® 
rabbit 
IHC 1:500 - - 
Cell Signaling 
WB 1:2,000 BSA 1:20,000 
MCM3 rabbit 
IHC 1:100 - - 
Cell Signaling 
WB 1:1,000 milk 1:20,000 
MCM4 (D3H6N) 
XP® 
rabbit 
IHC 1:100 - - 
Cell Signaling 
WB 1:1,000 milk 1:20,000 
MCM5 
[EP2682Y] 
rabbit 
IHC 1:200 - - Abcam, Berlin, 
Germany WB 1:500 BSA 1:20,000 
MCM6 
[EPR17686] 
rabbit 
IHC 1:4,000 - - 
Abcam 
WB 1:1,000 milk 1:20,000 
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Antigen 
(clone) 
Species Application Dilution 
Blocking 
agent 
Secondary 
dilution 
Company 
MCM7 (D10A11) 
XP® 
rabbit 
IHC 1:50 - - 
Cell Signaling 
WB 1:2,000 BSA 1:20,000 
RbAp48 rabbit WB 1:500 milk 1:20,000 Abcam 
SUZ12 
(D39F6) XP® 
rabbit 
IHC 1:100 - - 
Cell Signaling 
WB 1:1,000 BSA 1:20,000 
TAZ (V386) rabbit 
ChIP 2 µg - - 
Cell Signaling 
WB 1:1,000 BSA 1:20,000 
TEF-3 (N-G2) mouse ChIP 2 µg - - 
SANTA CRUZ 
biotech., Heidelberg, 
Germany 
Tri-Methyl- 
Histone H3 
(Lys27) (C36B11) 
rabbit 
IF 1:500 - 1:300 
Cell Signaling IHC 1:200 - - 
WB 1:400 BSA 1:20,000 
YAP rabbit WB 1:400 BSA 1:20,000 Cell Signaling 
YAP (D8H1X) XP® rabbit 
ChIP 2 µg - - 
Cell Signaling 
IHC 1:200 - - 
 
 
Table 2: Secondary antibodies. 
Antigen Isotype Application Company 
anti-rabbit Cy3 donkey IgG IF 
Jackson ImmunoResearch 
Europe Ltd., Ely, UK 
IRDye 680LT anti-mouse donkey IgG WB 
LI-COR Biosciences, Bad 
Homburg, Germany 
IRDye 800CW anti-chicken donkey IgG WB LI-COR Biosciences 
IRDye 800CW anti-rabbit donkey IgG WB LI-COR Biosciences 
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3.2 Bacteria and Supplements 
 Mach1 T1R competent bacteria cells (Invitrogen Ltd, Paisley, UK) 
 Ampicillin sodium salt (Sigma-Aldrich, Taufkirchen, Germany) 
 LB medium pH 7.0 (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl) 
 LB agar plates (LB medium + 1.5% (w/v) agar) 
3.3 Buffers and Solutions 
All chemicals were used in p. a. quality and were purchased from the following manufacturers, if 
not otherwise indicated:  
 AppliChem (Darmstadt, Germany) 
 Carl Roth (Karlsruhe, Germany) 
 Merck Millipore (Darmstadt, Germany) 
 SERVA (Heidelberg, Germany) 
 Sigma-Aldrich (Taufkirchen, Germany) 
Table 3: Reagents. 
Reagent Company 
30% Formamide Carl Roth 
3-Amino-9-ethylcarbazole DAKO 
99% Ethanol Carl Roth 
Acetone Carl Roth 
Agar BD Biosciences, Heidelberg, Germany 
AP-Polymer Detection Line DCS, Hamburg, Germany 
Cell Lysis Buffer 10x New England Biolabs, Frankfurt, Germany 
DAPI Fluoromount-G Southern Biotech, Birmingham, USA 
Dimethylsulfoxide Sigma-Aldrich 
distilled, DNAse/RNAse free water Gibco/Life Technologies, Darmstadt, Germany 
DNA loading dye 6x Thermo Fisher Scientific, Darmstadt, Germany  
dNTP Mix Thermo Fisher Scientific 
Dynabeads® Protein G Thermo Fisher Scientific 
Enhancer Detection Line DCS 
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Reagent Company 
Fetal bovine serum Gibco/Life Technologies 
Fisher’s EZ Run Pre-Stained Rec 
Protein Ladder 
Fisher Scientific, Schwerte, Germany 
Fugene® HD transfection reagent Promega, Mannheim, Germany 
GelRedTM Nucleic Acid Gel Stain Biotium, Hayward, USA 
GeneRulerTM 1kb DNA ladder Thermo Fisher Scientific, Darmstadt, Germany 
H2O2 block DAKO 
NEBuffer 1.1 New England Biolabs 
NEBuffer 2.1 New England Biolabs 
OligofectamineTM Life Technologies 
Opti-MEM Gibco/Life Technologies 
Penicillin/Streptomycin Sigma-Aldrich 
Permanent AP Red Zytomed, Berlin, Germany 
Phenylmethylsulfonylfluorid (PMSF) Sigma-Aldrich 
Phosphate buffered saline GE Healthcare, Solingen, Germany 
PhosStop 10x Roche, Mannheim, Germany 
Protease-Inhibitor Mix G 1000x SERVA, Heidelberg, Germany 
REAL Hematoxylin DAKO 
Resazurin Sigma-Aldrich 
RPMI-1640 Sigma-Aldrich 
Salmon sperm DNA 
Invitrogen/Thermo Fisher Scientific, Darmstadt, 
Germany 
Streptavidin-HRP DAKO 
Sulfuric acid Carl Roth 
Target Retrieval Solution (pH 6) DAKO 
Target Retrieval Solution (pH 9) DAKO 
Tazemetostat Biomol, Hamburg, Germany 
Tryptone BD Biosciences 
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Reagent Company 
Verteporfin Sigma-Aldrich 
Reagent Company 
Xylene Carl Roth 
Yeast extract BD Biosciences 
 
Table 4: Enzymes. 
Enzyme Company 
ABsolute qPCR SYBR Green ROX Mix Thermo Fisher Scientific, Darmstadt, Germany 
BbsI New England Biolabs 
HindIII New England Biolabs 
KpnI New England Biolabs 
Q5® High-Fidelity DNA Polymerase New England Biolabs 
RevertAid H Minus RT Thermo Fisher Scientific 
RPMI-1640 Sigma-Aldrich 
SacI New England Biolabs 
T4 DNA Ligase New England Biolabs 
T4 Polynucleotide Kinase New England Biolabs 
Trypsin-EDTA Sigma-Aldrich 
 
Table 5: Recipes of solutions and buffers. 
Solution/Buffer Recipe 
Blocking solution (B) 5% (m/v) BSA in TBST 
Blocking solution (M) 5% (m/v) skim milk in TBST 
Borate buffer (pH 8.8) 
20 mM Boric acid 
1.27 mM EDTA 
IP wash buffer 
100 mM Tris (pH 8.5) 
500 mM LiCl 
1% Igepal CA 630 
1% Na-Desoxycholate 
 
Materials 
22 
 
Solution/Buffer Recipe 
Loading buffer (4x) (pH 7.6) 
250 mM Tris (pH 8) 
8% SDS 
40% glycerol 
0.04% bromphenol blue 
100 mM DTT 
Nuclear extraction buffer 
10 mM Tris‐HCl 
10 mM MgCl2 
25 mM KCl 
1% Triton X‐100 
8.6% Sucrose 
200X protease inhibitor 
PBST (pH 7.4) 0.02% Tween-20 in PBS 
Phosphate buffered saline (PBS, pH 7.4) 
140 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
Protein isolation buffer 
1X Cell Lysis Buffer 
1X PhosStop 
1X Protease inhibitor 
RIPA buffer 
150 mM NaCl 
0.1% SDS 
0.5% Na-Desoxycholate 
1% Igepal CA 630 
5 mM EDTA 
50 mM Tris (pH 8) 
RIPAh 
150 mM NaCl 
0.1% SDS 
0.5% Na-Desoxycholate 
1% Igepal CA 630 
5 mM EDTA 
50 mM Tris (pH 8) 
1 mM PMSF 
10X Protease inhibitor 
SDS-Running buffer 
25 mM Tris 
192 mM Glycin 
0.1% (m/v) SDS 
TAE-Buffer (pH 8) 
40 mM Tris-Acetate 
1 mM EDTA 
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Solution/Buffer Recipe 
Talianidis elution buffer 
70 mM Tris (pH 8) 
1 mM EDTA 
1.5% (w/v) SDS 
TBST 0.1% (v/v) Tween-20 in TBS 
TE buffer 
70 mM Tris (pH 8) 
1 mM EDTA 
Tris buffered saline (TBS, pH 7.6) 
20 mM Tris-HCl 
140 mM NaCl 
 
3.4 Consumables 
Table 6: Consumables. 
Consumables Company 
Amersham Protran 
 0.45 μm Nitrocellulose Blotting 
Membrane 
GE Healthcare 
Microscope cover glasses Marienfeld, Lauda-Königshofen, Germany 
Microscope slides “Menzel-Gläser” Thermo Fisher Scientific 
Nunc™ 96-Well Polypropylene 
MicroWell™ Plates 
Thermo Fisher Scientific 
Precellys® Ceramic Kit 1.4 mm Peqlab, Erlangen, Germany 
WhatmanTM 3 mm Chr GE Healthcare 
Sterile stripettes® Corning, New York, USA 
Microcentrifuge tubes 
(0.2 mL; 1.5 mL; 2 mL) 
Eppendorf, Hamburg,Germany 
Sarstedt, Nümbrecht, Germany 
Greiner Bio-One, Frickenhausen, Germany 
Falcons (15 mL; 50 mL) 
Cell culture plates  
(15 cm; 10 cm; 6 well, 24 well, 96 well) 
Cell scrapers 
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3.5 ‘Ready to use’ Kits 
Table 7: Kits. 
Name Company 
AP based DCS Detection Line system DCS, Hamburg, Germany 
Avidin/Biotin blocking KIT Vector, Burlingame, USA 
Cell proliferation Biotrak Elisa System, version 2 GE Healthcare 
Clariom™ D Assay, human Applied BiosystemsTM 
Dual-Luciferase® Reporter Assay System Promega 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel, Düren, Germany 
NucleoSpin® RNA II kit Macherey-Nagel 
NucleoSpin Plasmid Macherey-Nagel 
PureYieldTM Plasmid Midipred System Promega 
Puregene® Core Kit A Qiagen 
 
3.6 Equipment 
Table 8: Equipment. 
Equipment Company 
12-Tube Magnet Qiagen, Hilden, Germany 
Agarose Gel Electrophoresis Systems 
von Keutz Labortechnik, Reiskirchen, 
Germany 
AlphaImagerTM gel documentation system Biozym, Hessisch Oldendorf, Germany 
Axiovert 25 microscope Zeiss, Oberkochen, Germany 
Bacteria Incubator Memmert, Schwabach, Germany 
BIOWIZARD Silver Line safety cabinet Ewald, Bad Nenndorf, Germany 
EV231 power supply Consort, Turnhout, Belgium 
FLUOstar Omega Microplatereader BMG Labtech, Ortenberg, Germany 
Hera Cell 150 CO2-Incubator Heraeus, Hanau, Germany 
Intelli-mixer overhead shaker Neolab, Heidelberg, Germany 
Kern EG scale Kern, Balingen-Frommern, Germany 
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Equipment Company 
KS15 orbital shaker with TH15 incubation 
hood 
Edmund Bühler, Hechingen, Germany 
Megafuge 16R Thermo Fisher Scientific 
Microwave R-208 SHARP, Hamburg, Germany 
Mikro 200R Hettich, Tuttlingen, Germany 
Mini Trans-Blot Cell Bio-Rad, Munich, Germany 
Mini-PROTEAN® 3 Cell SDS-gel 
electrophoresis systems 
Bio-Rad 
NanoDrop ND-1000 Spectrophotometer Thermo Fisher Scientific 
Neubauer counting chamber Brand, Frankfurt, Germany 
Odyssey Sa Infrared Imaging System LI-COR Biosciences 
Olympus CKX41 microscope Olympus, Hamburg, Germany 
pH 210 Microprocessor pH-Meter 
Hanna Instruments, Kehl am Rhein, 
Germany 
Precellys® 24 Homogeniser Peqlab, Erlangen, Germany 
PTC-200 Thermal Cycler Biozym, Hessisch Oldendorf, Germany 
Roll shaker CAT RM5 Neolab, Heidelberg, Germany 
S-4000 Sonicator Qsonica, Newton, USA 
Secuflow fume hood Waldner, Wangen, Germany 
StepOnePlusTM Real-Time PCR System Applied Biosystems, Darmstadt, Germany 
Thermomixer compact Eppendorf, Hamburg, Germany 
Transsonic T460/H ultrasound water bath Elma, Singen, Germany 
Universal 32R Hettich, Tuttlingen, Germany 
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3.7 Oligonucleotides 
DNA Oligonucleotides were purchased from Thermo Fisher Scientific, siRNAs were bought from 
Eurofins Genomics, Ebersberg, Germany. 
Table 9: Oligonucleotides used for RNA interference (siRNA). 
siRNA 
name 
Final 
conc. 
Target 
structure 
Sequence (5' - 3') 
mRNA accession 
number 
Final 
conc. 
#1EZ 20 nM EZH2 CAUCGAAAGAGAAAUGGAA-dT-dT NM_001203247 20 µM 
#2EZ 20 nM EZH2 AUAUUGAACCUCCUGAGAA-dT-dT NM_001203247 20 µM 
#1M2 20 nM MCM2 UGAGCUGUUGCUCUUCAUA-dT-dT NM_004526 20 µM 
#2M2 20 nM MCM2 CUACCAGCGUAUCCGAAUC-dT-dT NM_004526 20 µM 
#1M3 20 nM MCM3 AGACCAUAGAGCGACGUUA-dT-dT NM_002388 20 µM 
#2M3 20 nM MCM3 GCTTCTGAACAATGCCTTT-dT-dT NM_002388 20 µM 
#1M4 20 nM MCM4 GAAUUAGCUGAAGCAUUGA-dT-dT NM_005914 20 µM 
#2M4 20 nM MCM4 GCAGAAGATATAGTGGCAA-dT-dT NM_005914 20 µM 
#1M5 20 nM MCM5 GGAUGAACUCAAGCGGCAU-dT-dT NM_006739 20 µM 
#2M5 20 nM MCM5 CCACCAUCUUGUCGCGCUU-dT-dT NM_006739 20 µM 
#1M6 20 nM MCM6 AGAGGAGCGAGCUUGUUAA-dT-dT NM_005915 20 µM 
#2M6 20 nM MCM6 CACCUGAUGUCAAUCUAGA-dT-dT NM_005915 20 µM 
#1M7 20 nM MCM7 GCUCAUGAGGCGUUACAUA-dT-dT NM_005916 20 µM 
#2M7 20 nM MCM7 GAAGGAGAGAACACAAGGA-dT-dT NM_005916 20 µM 
#1M 40 nM 
#1MCM2 UGAGCUGUUGCUCUUCAUA-dT-dT NM_004526 3.3 µM 
#3MCM3 AGACCAUAGAGCGACGUUA-dT-dT NM_002388 3.3 µM 
#3MCM4 GAAUUAGCUGAAGCAUUGA-dT-dT NM_005914 3.3 µM 
#4MCM5 GGAUGAACUCAAGCGGCAU-dT-dT NM_006739 3.3 µM 
#1MCM6 AGAGGAGCGAGCUUGUUAA-dT-dT NM_005915 3.3 µM 
#1MCM7 GCUCAUGAGGCGUUACAUA-dT-dT NM_005916 3.3 µM 
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siRNA 
Name 
Final 
conc. 
Target 
structure 
Sequence (5' - 3') 
mRNA accession 
Number 
Final conc. 
#2M 40 nM 
#2MCM2 CUACCAGCGUAUCCGAAUC-dT-dT NM_004526 3.3 µM 
#4MCM3 GCTTCTGAACAATGCCTTT-dT-dT NM_002388 3.3 µM 
#4MCM4 GCAGAAGATATAGTGGCAA-dT-dT NM_005914 3.3 µM 
#5MCM5 CCACCAUCUUGUCGCGCUU-dT-dT NM_006739 3.3 µM 
#3MCM6 CACCUGAUGUCAAUCUAGA-dT-dT NM_005915 3.3 µM 
#2MCM7 GAAGGAGAGAACACAAGGA-dT-dT NM_005916 3.3 µM 
NTC - nonsense UGGUUUACAUGUCGACUAA-dT-dT - 20 µM 
#1S 20 nM SUZ12 GGAUGUAAGUUGUCCAAUA-dT-dT NM_001321207 20 µM 
#2S 20 nM SUZ12 ACAAGCCUGGUUCAGUUAA-dT-dT NM_001321207 20 µM 
#1Y 20 nM YAP CCACCAAGCUAGAUAAAGA-dT-dT NM_006106 20 µM 
#2Y 20 nM YAP GGUCAGAGAUACUUCUUAA-dT-dT NM_006106 20 µM 
#2T 20 nM TAZ AAACGUUGACUUAGGAACUUU-dT-dT NM_015472 20 µM 
#3T 20 nM TAZ AGGUACUUCCUCAAUCACA-dT-dT NM_015472 20 µM 
#1YT 40 nM 
#1YAP CCACCAAGCUAGAUAAAGA-dT-dT NM_006106 10 µM 
#2TAZ AAACGUUGACUUAGGAACUUU-dT-dT NM_015472 10 µM 
#2YT 40 nM 
#2YAP GGUCAGAGAUACUUCUUAA-dT-dT NM_006106 10 µM 
#3TAZ AGGUACUUCCUCAAUCACA-dT-dT NM_015472 10 µM 
#1T14 80 nM 
#1 TEAD1 GGACAUUCGUCAGAUUUAUGA-dT-dT NM_021961 10 µM 
#1 TEAD4 GGGCAGACCUCAACACCAA-dT-dT NM_201443 10 µM 
#2T14 80 nM 
#2 TEAD1 GAGCACAACAUCAUAUUUACA-dT-dT NM_021961 10 µM 
#2 TEAD4 CCGCCAAAUCUAUGACAAA-dT-dT NM_201443 10 µM 
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Table 10: PCR primer for chromatin-immunoprecipitation (ChIP). 
Genepromoter 
Genomic 
location 
Name Sequence (5‘-3‘) 
EZH2 -7q36.1 
Forward CCCCAACAGTTCATAGGTGAC 
Reverse GTCTCTCCTATTGCTTCATGTGGC 
MCM2 +3q21.3 
Forward CCGATATTTGAGCTGGCTTCTATTTG 
Reverse CTTGTCCTCCAACACACCAAACC 
MCM3 -6p12.2 
Forward AGACTCCATAATTCGGCTGC 
Reverse GGCTTTAAGTCTTGGGTTGCACA 
MCM5 +22q12.3 
Forward GGAGAGTCTTTGTCACCATAC 
Reverse CTTCGGCCTCCCAAAGTGC 
MCM6 -2q21.3 
Forward GACAGCAGAAGCGGCTTACTC 
Reverse GGCTGCTGGAACAAGTTCG 
MCM7 -7q22.1 
Forward GGGCCTCACGTTAGCTTTATTTG 
Reverse CCTCCCAGGACTGGTTCATTG 
RBBP7 -Xp22.2 
Forward CCTTCTCTGACCCTCACTG 
Reverse CGGCTTGGGAGATGATTTGTATC 
SUZ12 +17q11.2 
Forward GCAAAGGCTTTGATAAAACCTGTACTTTAGG 
Reverse GGGTTCTCTATAGTTAACTGCAAAACACTG 
 
Table 11: PCR primer for semi-quantitative real-time PCR (qPCR) for human genes. 
Gene mRNA accession number  Sequence (5‘-3‘) 
B2M NM_004048 
Forward CACGTCATCCAGCAGAGAAT 
Reverse TGCTGCTTACATGTCTCGAT 
EED NM_001308007 
Forward AAGGAGAAATCCGGTTGTTGC 
Reverse AGCAGAGGATGGCTCGTATTG 
EZH1 NM_001991 
Forward GAGAAGTTCTGCCAGTGCAACC 
Reverse TGACTGAACAGGTTGGACACG 
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Gene mRNA accession number  Sequence (5‘-3‘) 
EZH2 NM_004456 
Forward GAGAGTGTGACCCTGACCTCTG 
Reverse CGTCAGATGGTGCCAGCAATAG 
MCM2 NM_004526 
Forward GAAATCGTGGCCGAGTTCTTC 
Reverse AATGCTGTTGATGCCGAATG 
MCM3 NM_002388 
Forward TGTGTGGAGGGCATTGTCACT 
Reverse CCACCAGGGTGGTGAGATCAG 
MCM4 NM_005914 
Forward CAGCCCTCCCCAAATGCATTC 
Reverse GTGTGCCCCTAACACCACTTC 
MCM5 NM_006739 
Forward TTGTACAAGCAGCCAGCCGA 
Reverse CAGGCTACGAATGCTGGAAGG 
MCM6 NM_005915 
Forward CTTACCTGTGTCGGGCCTTGA 
Reverse ACTGTCTGACAGTCCAAGCACA 
MCM7 NM_005916 
Forward AGTGCCAAACCAACCGCTCA 
Reverse CTCCTTCTACCAGCACCGTGA 
PPIA NM_021130 
Forward CCGCCGAGGAAAACCGTGTA 
Reverse TCTTTGGGACCTTGTCTGCAA 
RBBP4 NM_005610 
Forward TCTCCTGGAATCCCAATGAACC 
Reverse TTCTGGATCCACGCTTCCTTC 
RBBP7 NM_002893 
Forward TACCGTTCAGTGGCTTCCTG 
Reverse ACTCGAGCAACCACCAGATG 
RPL41 NM_001035267 
Forward AAACCTCTGCGCCATGAGAG 
Reverse AGCGTCTGGCATTCCATGTT 
SUZ12 NM_015355 
Forward GGACCAGTTAAGAGAACACC 
Reverse AGACATGCTTGCTTTTGTTCG 
TEAD1 NM_021961 
Forward GACAGTCACCTGTTCCACCAAAG 
Reverse CCATTCTCAAACCTTGCATACTCCG 
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Gene mRNA accession number  Sequence (5‘-3‘) 
TEAD2 NM_001256658 
Forward CTCACCTGTTCCTCCAAGGTC 
Reverse CACCAGGTACTCGCACATGG 
TEAD3 NM_003214 
Forward TTCATGGAGGTGCAGCGAGAC 
Reverse CGCACATCTACTGCCTCCAG 
TEAD4 NM_201443 
Forward TGGAGTTCTCTGCCTTCCTG 
Reverse GGACTGGCCAATGTGCACGA 
WWTR1 
(TAZ) 
NM_015472 
Forward CAGAGAATCCAGATGGAGAG 
Reverse GTTGACAGCAGCCTGAACTG 
YAP1 NM_006106 
Forward CCTGCGTAGCCAGTTACCAA 
Reverse CCATCTCATCCACACTGTTC 
 
Table 12: PCR primer for semi-quantitative real-time PCR (qPCR) for murine genes. 
Gene mRNA accession number  Sequence (5‘-3‘) 
ACTB NM_007393 
Forward GCTTCTTTGCAGCTCCTTCGT 
Reverse ACCAGCGCAGCGATATCG 
EED NM_021876 
Forward GAAGGAGACCCTCTGGTGTTTG 
Reverse CTGCTAATAGAGGGTGGCTGG 
EZH1 NM_007970 
Forward TGGGTGACGAGGTGAAGGAAG 
Reverse CGTCCTCCTCCTCATCAGAGT 
EZH2 NM_001146689 
Forward CTGAAACTGGGGGAGAGAAC 
Reverse GGAGGTTCAATATTTGGCTTC 
GAPDH NM_008084 
Forward TGTCCGTCGTGGATCTGAC 
Reverse CCTGCTTCACCACCTTCTTG 
HPRT NM_013556 
Forward TCCTCCTCAGACCGCTTTT 
Reverse CCTGGTTCATCATCGCTAATC 
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Gene mRNA accession number 
 
Sequence (5‘-3‘) 
MCM2 NM_008564 
Forward CCATTTGAAGATGAGTCTGAGGG 
Reverse AGACATCGAGCTCCGGAATG 
MCM3 NM_008563 
Forward GTGAATGACCTGCGCAGGAAG 
Reverse CGTAGGTGGCGTCAATGGAG 
MCM4 NM_008565 
Forward GGGCAGACACCTCACACTATTG 
Reverse CAAGGCCATGCAGACGTTT 
MCM5 NM_008566 
Forward CCCGTCGAGCATTCGGATTC 
Reverse GAGTAGCCTTGGCACGGACT 
MCM6 NM_008567 
Forward GCCCAAGCTGGTGACAGATG 
Reverse GATCTCTGACACCAAGGGCC 
MCM7 NM_008568 
Forward CCAGGAGTGCCAGACCAATC 
Reverse GGCTGGGCAATTCTTGTGTTCT 
PPIA NM_008907 
Forward AGCTGTCCACAGTCGGAAAT 
Reverse GCATACAGGTCCTGGCATCT 
RBBP4 NM_009030 
Forward AGTGAGTTCATTCTTGCCACAGG 
Reverse GAGGTGACCACTGAACTTGGAAT 
RBBP7 NM_009031 
Forward AGCTGTTGTAGAGGATGTGGCC 
Reverse GCTGTAGGGATTGAATGAGAGGC 
SUZ12 NM_199196 
Forward GCACTCTGAACTGCCGTAAACTG 
Reverse CTGCATAGGAGCCATCATAACACTC 
TBP NM_013684 
Forward TTGTCTGCCATGTTCTCCTG 
Reverse CAGGGTGATTTCAGTGCAGA 
TEAD4 NM_011567 
Forward CAAGGCCGCAGCATAGCTAG 
Reverse CTGGCTGATGTGCACAAACAGG 
TPX2 NM_001141977 
Forward GTATGTGCCCATTGCACAGCAG 
Reverse GTTCACAGATTTGGAGGGTAACAAGC 
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Gene mRNA accession number 
 
Sequence (5‘-3‘) 
TTK NM_009445 
Forward GTGTGTTCCAGAACCCTGCTG 
Reverse GGTGTCTCACAAGCAGACTTTGG 
TUBB5 NM_011655 
Forward TCACTGTGCCTGAACTTACC 
Reverse GGAACATAGCCGTAAACTGC 
WWTR1 
(TAZ) 
NM_001168281 
Forward CCAATGCACTGACCACTCAGC 
Reverse CTCATATCTGTGCTCATGGCAGG 
YAP1 NM_001171147 
Forward GACTCCGAATGCAGTGTCTT 
Reverse ATCGGAACTATTGGTTGTCA 
 
Table 13: Primer for cloning: luciferase vectors. 
Genepromoter Genomic location Name Sequence (5‘-3‘) 
MCM7 -7q22.1 Forward1 ATTACACTAGGTACCCCGAG 
MCM7 -7q22.1 Forward2 GTGACCACCAAATAGAGGC 
MCM7 -7q22.1 Reverse1 CCTTCACTGAGTCCTTCCA 
MCM3 -6p12.2 Forward1 CGACTTTGGTGGAGGTAGTTC 
MCM3 -6p12.2 Reverse1 GGTCCATGCTGTTATTCCCA 
 
Table 14: Oligonucleotides for cloning: CRISPR plasmids. 
Target of guide 
RNA 
Name Sequence (5‘-3‘) 
MCM2 Sense guide ACCTGAGAACCTGGAGGATCTCAA 
MCM2 Antisense guide AAACTTGAGATCCTCCAGGTTCTC 
 
Table 15: Sequencing Primer. 
Name Sequence (5‘-3‘) 
Luc-F AGTCAAGTAACAACCGCGA 
Luc-N Rev CATAGCCTTATGCAGTTGCTCTCC 
Amp_rev GCTATGTGGCGCGGTATTAT 
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Table 16: Plasmids. 
Name Function Backbone Resistance 
Additional 
feature 
CRISPR-MCM2 
sgRNA against 
MCM2 
pX458-ΔCas9 
Ampicillin, 
Puromycin 
GFP 
CRISPR-0 - pX458-ΔCas9 
Ampicillin, 
Puromycin 
GFP 
pRL_TK - pRL Ampicillin Renilla Luciferase 
MCM2-Firefly MCM2 promoter pGL3 Ampicillin Firefly Luciferase 
MCM3-Firefly MCM3 promoter pGL3 Ampicillin Firefly Luciferase 
MCM4-Firefly MCM4 promoter pGL3 Ampicillin Firefly Luciferase 
MCM6-Firefly MCM6 promoter pGL3 Ampicillin Firefly Luciferase 
MCM7-Firefly MCM7 promoter pGL3 Ampicillin Firefly Luciferase 
18ABJOTP MCM2 promoter pMK-RQ Kanamycin - 
18ABJOSP MCM4 promoter pMK-RQ Kanamycin - 
18ABJORP MCM6 promoter pMK-RQ Kanamycin - 
 
3.8 Software 
Table 17: Software. 
Name Company 
ApE v2.0.47 www.biologylabs.utah.edu/jorgensen/wayned/ape  
Aperio ImageScope v11.0.2.725 Leica Biosystems, Nussloch, Germany 
CCTop https://CRISPR.cos.uni-heidelberg.de/ (69) 
CellSens Dimension Olympus, Hamburg, Germany 
COBALT (Constraint-based Multiple 
Alignment Tool) 
https://www.ncbi.nlm.nih.gov/tools/cobalt/ (70) 
Inkscape 0.92.3 www.inkscape.org 
Fiji (ImageJ v1.46j) www.fiji.sc 
IBM SPSS Statistics 23.0 IBM, Ehningen, Germany 
Image Studio v3.1.4 LI-COR Biosciences, Bad Homburg, Germany 
JASPAR http://jaspar.genereg.net/ (71) 
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Name Company 
Omega v3.00 R2 BMG Labtech, Ortenberg, Germany 
R i386 3.2.3 https://www.R-project.org 
StepOne software v2.3 Applied Biosystems, Darmstadt, Germany 
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4 Methods 
4.1 Cell Culture 
4.1.1 Cultivation of Cells 
All cell lines in this study were cultured at 37°C in a 5% CO2 humid atmosphere, passaged twice 
a week and discarded after 6 month or 50 passages. The cells were detached using Trypsin-
EDTA, 2 mL per plate, and split into new dishes containing the corresponding medium (Table 18) 
supplemented with 10% FCS and 1% penicillin/streptomycin. 
Table 18: Background and culture information of cell lines. 
Cell line 
Donor 
Gender 
Donor 
Age 
[years] 
Tissue Tumor type Medium Provider 
HepG2 male 15 liver hepatoblastoma RPMI 
LGC Standards GmbH, 
Wesel Germany 
HepG2-
Cas9 
male 15 lLiver hepatoblastoma RPMI 
S. Luiken (AG 
Roessler), Heidelberg, 
Germany 
Sk-Hep1 male 52 
liver/ 
ascites 
adenocarcinoma DMEM LGC Standards GmbH 
HLF male 68 liver 
non-differentiated 
hepatoma 
DMEM 
JCRB Cell Bank, Osaka, 
Japan 
  
For cryo-conservation, sub-confluent cells from one 10 cm plate dish were trypsinized and 
resuspended in 2 mL medium supplemented with 10% DMSO. The vials were slowly cooled 
down to -80°C within 24 h and then transferred to the vapor phase of liquid nitrogen (-196°C). 
For revitalization, cells were rapidly thawed at 37°C, dissolved in 10 mL medium, centrifuged at 
300 x g for 5 min and resuspended in 10 mL medium before being transferred to a 10 cm dish. 
4.1.2 Seeding Cells 
Cells were seeded according to Table 19 for each experiment. Therefore cells were trypsinized, 
counted in a Neubauer chamber and resuspended in the respective medium. 
Table 19: Seeding cells. 
Cell line 6-well-plate 24-well-plate 
HepG2 100,000/well 
 
30,000/well 
100,000/well 
HepG2-Cas9 - 100,000/well 
Sk-Hep1 80,000/well - 
HLF 80,000/well 20,000/well 
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4.1.3 Transfection of siRNAs 
For RNAi-experiments cells were seeded into 6-well plates according to section  4.1.2 and used 
for transfection the following day. Untreated and nonsense siRNA-transfected cells were used 
as negative controls. Therefore, siRNAs and OligofectamineTM were each diluted in Opti-MEM 
according to Table 20. After incubation for 10 min at room temperature, both solutions were 
mixed and incubated for 15 min. Prior to the addition of respective transfection solution 
mixtures (A+B), cells were washed with PBS and covered with 800 µL Opti-MEM. After 24 h, the 
medium was replaced and cells were harvested after an additional culture time of 24 or 48 h. 
Table 20: Transfection protocol for siRNAs. 
A     B  
Final conc. 20 nM 40 nM 80 nM  Opti-MEM 10 µL 
Opti-MEM 184 µL 183 µL 181 µL  Oligofectamin 5 µL 
siRNA(20 µM) 1 µL 2 µL 4 µL    
4.1.4 Substance Treatment 
The EZH2 inhibitor Tazemetostat and the YAP/TEAD inhibitor Verteporfin were dissolved in 
DMSO to prepare 0.2 mM and 2 mM stock solutions, respectively. Cells were seeded into 6-well 
plates one day prior to treatment and then incubated with the indicated concentrations for 
24 h, followed by a medium exchange. After an additional 24 h of cultivation, cells were 
harvested and DMSO-treated cells served as a negative control. 
4.2 Human and Mouse Sample Analysis 
4.2.1 Tissue Microarray (TMA) 
A HCC TMA was evaluated after immunohistochemical staining for YAP, Ki67, and potential 
target genes. The TMA contained 105 HCCs (grading: G1: n=10, G2: n=75, G3: n=16, G4: n=4) 
and 7 normal liver tissues, evaluated by a pathologist (Prof. Dr. S. Singer). For each tissue 
sample, a score was derived from the scoring system (Table 21) and the product of the 
qualitative and quantitative parameters was calculated (range: 0-12). The evaluation was 
performed by two experienced investigators, independently. 
Table 21: Scoring system for TMA evaluation. 
score 
Quality 
-staining intensity- 
Quantity 
-positive cells- 
0 negative no expression 
1 low < 1% 
2 medium 1 - 9% 
3 strong 10 - 50% 
4 - > 50% 
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4.2.2 Statistical and Survival Analysis 
Basic statistic tests were performed using SPSS and R software. All data were presented as a 
mean ± standard deviation. Significance levels were defined as * p ≤ 0.05, ** p ≤ 0.01 and 
*** p ≤ 0.001. Statistical comparison was conducted using the two-tailed Mann-Whitney U test 
or the Student's t-test. 
Analysis of target gene expression correlation to overall survival and cancer recurrence (Kaplan-
Meier) were performed on transcriptome and clinical data of 242 HCC patients (cohort 1)(72) 
and 370 liver cancer patients (cohort 2)(27). Statistical tests, such as log-rank and Breslow test, 
were performed using the IBM SPSS Statistics software. Correlation analysis was performed 
using the Pearson’s Chi2-test and Spearman’s rank correlation analysis (rS). 
4.2.3 Transgenic Mice 
All experiments were approved by the German Regional Council of Baden-Wuerttemberg 
(Karlsruhe, Germany) and performed in accordance with the institutional regulations of the IBF 
(Interfakultäre Biomedizinische Forschungseinrichtung, University of Heidelberg). Mouse 
samples of different experiments were kindly provided by group members (AG Breuhahn, 
Institute of Pathology, Heidelberg, Germany). 
Briefly, transgenic mice (Col1A1-YAPS127A-LAP-tTA)(61) were housed and bred at the IBF and 
genotyping PCR performed on genomic DNA isolated from tail biopsies. During breeding, the 
transgene expression (YAPS127A) was suppressed by doxycycline supplementation of the drinking 
water. 
Doxycycline was withdrawn eight weeks after birth to induce hepatic YAPS127A overexpression. 
Total liver samples for RNA isolation were obtained from liver tissues 8 or 12 weeks after 
doxycycline deprivation. Hepatocyte isolation of transgenic and wildtype mice was performed 
10 weeks after doxycycline withdrawal. 
4.3 Methods of Molecular Biology 
4.3.1 Luciferase Plasmid Cloning  
Isolation of genomic DNA 
Total genomic DNA was isolated from cultured HLF cells using the Puregene® Core Kit A 
according to the manufacturer’s instructions. 
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Polymerase Chain Reaction (PCR) 
For amplification of the MCM3 and MCM7 promoter sites, genomic DNA was amplified using 
Q5-High Fidelity DNA Polymerase. The reaction setup is described in Table 22 and the cycling 
conditions in Table 23. The PCR product of the first MCM7-PCR (Forward1, Reverse1) was 
purified employing agarose gel electrophoresis and used as DNA-template for the second 
MCM7-PCR (Forward2, Reverse1) described in Table 22 and Table 23. 
Table 22: PCR master mix for luciferase cloning. 
Reagent Volume Final concentration 
5X Q5® Reaction Buffer 10 µL 1X 
dNTPs [10 mM] 1 µL 200 µM 
Forward primer [10 µM] 5 µL 0.5 µM 
Reverse primer [10 µM] 5 µL 0.5 µM 
DNA-Template 100 ng 2 µg/mL 
Q5® High-Fidelity DNA Polymerase 0.5 µL 20 U/mL 
dH2O ad 50 µL 
 
 
Table 23: Thermocycling conditions for luciferase cloning PCR. 
Step Description Temperature Time Cycles 
1 Initial denaturation 95°C 30 s 1 X 
2 Denaturation 95°C 30 s 
30 X 3 Annealing 
66°C (MCM3) 
30 s 59°C (1. MCM7) 
55°C (2. MCM7) 
4 Elongation 95°C 1 min 
5 Final elongation 72°C 10 min 1X 
 
Restriction enzyme digestion 
To introduce the MCM promoters upstream of the firefly luciferase gene in the pGL3_basic 
plasmid, sticky-end cloning was employed. Therefore the PCR products, pGL3-basic and ordered 
plasmids (MCM2, MCM4, MCM6) were digested for 1 h at 37°C with the respective enzymes 
depicted in Table 24 and purified employing agarose gel electrophoresis. 
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Table 24: Digestion conditions. 
 
reaction buffer Enzyme 
MCM2 NEBuffer 2.1 KpnI HindIII 
MCM3 NEBuffer 1.1 SacI KpnI 
MCM4 NEBuffer 2.1 HindIII HindIII 
MCM6 NEBuffer 2.1 KpnI HindIII 
MCM7 NEBuffer 1.1 SacI KpnI 
 
Agarose gel electrophoresis 
PCR products and digested plasmids were visualized and purified using agarose gel 
electrophoresis. For this purpose, a 1% agarose gel was prepared using melted agarose in TAE 
buffer, supplemented with 20 µL/L GelRedTM Nucleic Acid Gel Stain as a DNA intercalator for 
visualization of DNA fragments under to UV light. The agarose solution was poured into gel trays 
and solidified. DNA was mixed with 6x DNA loading dye and loaded onto the agarose gel next to 
a DNA size marker (GeneRuler 1 kb DNA ladder). Fragments were separated by applying 100 V 
for 1 h. PCR products were visualized using the AlphaImagerTM gel documentation system. The 
agarose gel piece containing the desired PCR product was cut out of the gel. 
DNA PCR and gel purification 
Purification of PCR products or digestion products was performed by using the NucleoSpin® Gel 
and PCR Clean-up KIT according to the manufacturer’s instructions. 
Ligation 
To ligate the digested fragments, MCM promoter regions with the pGL3-basic backbone, the 
purified insert (200 ng) was added to the vector (400 ng), together with T4 ligase (5 units) and 
T4 Buffer and incubated at room temperature for 1 h. 
4.3.2 CRISPR Plasmid Cloning 
CCTop-software (69) was used to identify specific target sites within the exons 3-6 and 
corresponding oligonucleotides were ordered. In order to obtain the inserts, the respective 
oligonucleotides were annealed and phosphorylated with T4 polynucleotide kinase (Table 25), 
following thermocycling conditions displayed in Table 26. 
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Table 25: Reaction mix for phosphorylation and annealing. 
Reagent Volume Final concentration 
10X T4 DNA ligase Buffer 1 µL 1 U/µL 
T4 Polynucleotide Kinase 1 µL 1 X 
Sense guide [10 µM] 1 µL 1 µM 
Antisense guide [10 µM] 1 µL 1 µM 
dH2O 6 µL  
 
Table 26: Thermocycling conditions for phosphorylation and annealing. 
Description Temperature Time 
Phosphorylation 37°C 30 min 
Denaturation 95°C 5 min 
Annealing -0.1°C s-1 
 
The annealed insert was diluted with water (1:10) with water and cloned into the pX458-ΔCas9-
vector using the restriction enzyme BbsI according to the protocol shown in Table 27 and using 
the thermocycling conditions listed in Table 28. 
Table 27: Reaction mix for digestion and ligation. 
Reagent Volume Final concentration 
10X T4 DNA ligase Buffer 2 µL 1X 
BbsI 1 µL 0.5 U/µL 
T4 ligase 1 µL 0.25 U/µL 
Insert (annealed and phosphorylated 
guides, dilution 1:10) 
1 µL 
 
pX458-ΔCas9-Vector 100 ng 5 ng/µL 
dH2O ad 20 µL  
 
Table 28: Thermocycling conditions for digestion and ligation. 
Description Temperature Time Cycles 
Digestion 37°C 10 min 
6X 
Ligation 22°C 10 min 
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4.3.3 Transformation of Competent Bacteria and Plasmid Isolation 
Plasmids were transformed into competent bacteria via heat shock. Freshly thawed bacteria 
were mixed with Ligation-mixture, incubated on ice for 15 min and heat-shocked at 42°C for 
45 s. The mixture was cooled on ice, plated on LB-Agar plates with Ampicillin (50 μg/mL), and 
incubated at 37°C overnight. Single colonies were picked the next day and expanded in 5 mL 
(Miniprep) or 100 mL LB medium (Midiprep) containing Ampicillin and incubated at 37°C under 
shaking overnight. For long-term storage, bacteria cultures were mixed 1:1 with 70% glycerol 
and frozen at -80°C.  
Isolation of plasmid DNA was carried out with NucleoSpin® Plasmid kit (Miniprep) or PureYieldTM 
Plasmid Midiprep System kit (Midiprep) according to the manufacturer’s instructions. 
4.3.4 Sequencing 
Sequencing reactions were carried out by the Microsynth AG (Balgach, Switzerland). Sequencing 
results were analyzed using the software ApE-A plasmid Editor v2.049.10. 
4.3.5 Isolation of Total RNA and cDNA Synthesis 
Total RNA of cultured cells was isolated using the NucleoSpin® RNA II kit according to the 
manufacturer’s instructions. For isolation of RNA from tissue samples, small tissue pieces were 
homogenized using the Precellys® Ceramic Kit 1.4 mm and the Precellys® 24 Homogeniser 
(2X 20 s, 6,000 x g). After centrifugation, the supernatant was used for further RNA isolation 
with the NucleoSpin® RNA II kit. 
Total RNA concentration was determined by measuring the absorption at 260 nm using a 
spectrophotometer. The ratio of 260 nm to 280 nm of absorbance was used to assess the purity, 
(ratio ≥1.9 for RNA). Total RNA was transcribed into cDNA by mixing 1 µg of isolated RNA with 
dNTPs (1 mM) and random Hexamer primer (5 μM). The mixture was first incubated at 75°C for 
5 min and then cooled to 25°C. After the addition of 5X reaction buffer and RevertAid H Minus 
Reverse Transcriptase (RT), the reverse transcription was performed at 42°C for 1 h and stopped 
at 70°C for 10 min in a thermal cycler. 
4.3.6 Semi-Quantitative Real-Time PCR (qPCR) 
Real-time PCR was used to analyze mRNA expression. Therefore 2 µL of cDNA (1:50) was mixed 
with 2X ABsolute QPCR SYBR Green ROX Mix, forward primers (0.3 µM) and reverse primers (0.3 
µM). Samples were analyzed in duplicates, water-samples were used as negative control and 
melting curve analysis was performed to check for PCR specificity. The qPCR was performed on 
a StepOnePlus™ Real-Time PCR System with the cycling conditions and melting curve program 
listed in Table 29.  
Relative gene expression was calculated using the ΔΔCT-method and normalized to Ribosomal 
Protein L41 (RPL41). For the analysis of gene expression in murine tissue samples, a panel of 
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housekeeping genes (Actb, Gapdh, Hprt, Ppia, Tbp,Tubb5) was evaluated using the geNorm 
algorithm to find the most stable reference gene (73) 
Table 29: Thermocycling conditions for qPCR. 
Part Step Description Temperature Time Cycles 
PCR 
1 Initial denaturation 95°C 15 min 1 X 
2 Denaturation 95°C 15 s 
40 X 
3 
Annealing and 
elongation 
60°C 60 s 
Melting 
curve 
4 Denaturation 95°C 15 s 
1X 
5 Annealing 60°C 30 s 
6 Stepwise dissociation 60-95°C 0.5°C/s 
7 Final denaturation 95°C 15 s 
 
4.4 Methods of Protein Biochemistry 
4.4.1 Total Protein Isolation and Quantification 
Cultured cells were washed two times with PBS and scraped in 60 µL/well protein isolation 
buffer. The samples were sonicated in an ultrasound water bath three times for 20 s and cooled 
on ice in between. Centrifugation at 14,000 x g at 4°C for 10 min removed cell debris and 
protein concentration was determined by measuring the absorption of 2 µL sample at 280 nm 
using a Nanodrop spectrophotometer. 
4.4.2 Protein and Histone Isolation  
Cultured cells were washed two times with PBS, scraped in nuclear extraction buffer and 
incubated on ice for 5 min. Centrifugation at 600 x g for 5 min at 4°C separated chromatin-
bound proteins in the pellet from the soluble proteins. The supernatant was collected and 
protein concentration was determined using a Nanodrop spectrophotometer. The pellet was 
washed with 200 µL TE buffer (pH 7.4), resuspended in 50 µL 0.2 M sulfuric acid and incubated 
for one hour on ice. After centrifugation at 10,000 x g for 10 min at 4°C, the supernatant was 
transferred into a tube containing 500 µL of ice-cold acetone and incubated overnight at -20°C. 
Precipitated histones were pelleted at 10,000 x g for 10 min at 4°C and resuspended in 20 µL 
water.  
4.4.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
SDS-PAGE was used to separate proteins according to their molecular weight. Therefore, 100 µg 
of total protein or 5 µL of isolated histones, in 20 µL total volume, were mixed with 7 µL Loading 
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buffer and denaturated for 10 min at 95°C. The samples were loaded with 2 µL of a protein size 
marker on polyacrylamide gels, which were prepared as described in Table 30. Electrophoretic 
separation was carried out at 120 V for 1.5 h. 
Table 30: Preparation of SDS-polyacrylamide gel. 
Substance 8% separation gel 15% separation gel stacking gel 
Acrylamide 8% (v/v) 15% (v/v) 5% (v/v) 
Tris-HCl, pH 8.8 375 mM 375 mM - 
Tris-HCl, pH 6.8 - - 125 mM 
SDS 0.1% (w/v) 0.1% (w/v) 0.1% (w/v) 
APS 0.1% (v/v) 0.1% (v/v) 0.1% (v/v) 
TEMED 0.06% (v/v) 0.04% (v/v) 0.1% (v/v) 
 
4.4.4 Immunoblotting 
Proteins were transferred from SDS-gels to nitrocellulose membranes using a wet blot chamber 
at 95 V and 450 mA for 1.5 h with ice-cold borate buffer. Membranes were blocked for 30 min 
in 5% BSA or milk in TBST and primary antibodies added according to Table 1. After overnight 
incubation at 4°C, membranes were washed three times with TBST and incubated for 1 h at 
room temperature with suitable secondary antibodies as shown in Table 2. After washing the 
membranes three times with TBST, the Odyssey Sa Infrared Imaging System was used to detect 
the fluorescence signals.  
4.4.5 Immunofluorescence 
Cultured cells were washed with PBS and fixated for 15 min with 4% PFA-solution. After 
permeabilization with 0.2% TritonX for 12 min, cells were washed two times for 5 min with PBS 
and blocked for 30 min with 1% BSA in PBS. Incubation with a primary antibody according to 
Table 1 for 1 h at room temperature was followed by three times washing, each for 5 min in PBS 
and incubation with secondary antibody for 1 h at room temperature described in Table 2. The 
samples were sequentially washed for 5 min in PBS (3x), VE-water (1x), 99% Ethanol (1x), 
airdryed and mounted with DAPI-containing Fluoromount-G™. Slides were stored at 4°C and 
images were taken at the Olympus CKX41 microscope. 
4.4.6 Immunohistochemistry (IHC) 
All IHC stains were performed by the central IHC research facility at the Institute of Pathology, 
Heidelberg. Paraffin-embedded tissues were cut with a microtome to 3 μm sections, which were 
mounted on microscope slides and dried overnight. Deparaffinization was performed three 
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times by incubation in xylene for 5 min and followed by rehydration of the tissue. The slides 
were sequentially submitted to 100% ethanol (2x), 96% ethanol (2x), 70% ethanol (1x), and 
finally aqua dest for 2 min each. The tissue sections were then incubated in a steamer or 
pressure cooker in antigen retrieval-buffer according to Table 31. Slides were washed in TBS or 
TBST, blocked with avidin and biotin (Avidin/Biotin Blocking Kit), and washed with TBS/TBST, 
followed by primary antibody incubation in a wet chamber at 4°C overnight. After washing twice 
with TBS/TBST for 5 min, the tissue sections were incubated with biotinylated secondary 
antibody or Enhancer Detection Line for 25 min, followed by 2x 5 min TBS/TBST washes, H2O2 
block for 10 min, 2x TBS/TBST washes for 5 min, Streptavidin-HRP or AP-Polymer Detection Line 
incubation for 20 min, 2x TBS/TBST washes for 5 min and AEC (3-amino-9-ethylcarbazole) or 
Permanent AP Red development. For nuclear visualization, tissue sections were washed 2x with 
TBS for 5 min and incubated with REAL Hematoxylin. 
Table 31: Antibody retrieval and detection conditions for IHC. 
Antigen Detection Detection system Pretreatment 
Citrate 
buffer 
EZH2 
Permanent AP 
Red 
DCS 2red SuperVision 
rabbit 
pressure cooker pH 6 
SUZ12 
Permanent AP 
Red 
DCS 2red SuperVision 
rabbit 
pressure cooker pH 6 
YAP 
Permanent AP 
Red 
DCS 2red SuperVision 
rabbit 
pressure cooker pH 6 
Ki67 AEC Dako  5003 steamer pH 9 
Tri-Methyl-Histone 
H3 (Lys27) 
Permanent AP 
Red 
DCS 2red SuperVision 
rabbit 
steamer pH 9 
MCM4 Fancy Red 
DCS 2red SuperVision 
rabbit 
steamer pH 6 
MCM5 
Permanent AP 
Red 
DCS 2red SuperVision 
rabbit 
steamer pH 6 
MCM6 
Permanent AP 
Red 
DCS 2red SuperVision 
rabbit 
steamer pH 6 
MCM2 
Permanent AP 
Red 
DCS 2red SuperVision 
rabbit 
pressure cooker pH 6 
MCM3 Fancy Red 
DCS 2red SuperVision 
rabbit 
steamer pH 9 
MCM7 
Liquid 
Permanent 
Red 
DCS 2red SuperVision 
rabbit 
steamer pH 9 
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4.5 Functional Assays 
4.5.1 5-Bromo-2’-Deoxyuridine (BrdU) Incorporation Assay 
BrdU assay was performed to quantify DNA synthesis in proliferating cells. Therefore, cells were 
seeded in 6-well plates and treated with siRNAs against YAP, TAZ, and MCMs as described in 
4.1.3. One day after inhibition, cells were trypsinized and seeded on 96-well plates in 
quadruplicates. BrdU assay was performed with Cell Proliferation Biotrak Elisa System the 
following day according to manufacturer’s instruction. Briefly, cells were incubated with BrdU 
for one hour at 37°C, followed by 30 min fixation and 30 min blocking at room temperature. 
Incubation with BrdU-antibody (1:100) for one hour and three washing steps were performed at 
room temperature. Addition of TMB-substrate starts the peroxidase reaction, which was 
stopped after 5 min using 1 M sulfuric acid. Absorbance at 450 nm was measured using a 
microplate reader (FLUOstar Omega).  
4.5.2 Chromatin Immunoprecipitation (ChIP) 
For ChIP experiments, 3,000,000 cells were seeded in a 15 cm dish, one day prior to the 
experiment (one plate per two IPs). After washing with PBS, cells were fixed with 1% 
formaldehyde/PBS at room temperature for 15 min. The crosslinking was stopped by adding 
glycine to a final concentration of 125 mM for 5 min and two times washing with cold PBS. Cells 
were harvested in 1 mL cold RIPAh/15 cm plate and sonicated to generate fragments of 
genomic DNA (<500 bp). Cell debris were removed by centrifugation at 16,000 x g at 4°C for 15 
min and 0.5 mL protein lysates/IP precleared with Dynabeads® Protein G. Therefore, magnetic 
beads were washed with RIPA buffer and incubated with lysates at 4°C for 1.5 h with rotation. 
Meanwhile, the Dynabeads for IP were prepared by washing with RIPA buffer and blocking with 
BSA (1 mg/mL) and salmon sperm DNA (0.3 mg/mL) at 4°C for 1.5 h with rotation. Two percent 
of precleared lysates were added in Talianidis elution buffer and stored at -20°C until further 
processing (input sample). After washing with RIPA, the blocked beads were resuspended in 
0.5 mL RIPA per IP and added to precleared lysates with 2 µg antibody followed by incubation at 
4°C overnight with rotation. The beads were washed successively with RIPA buffer, two times 
with IP wash buffer and again RIPA buffer, each time with 5 min rotation in between. 
Subsequently, beads were shortly washed with TE buffer and immunocomplexes were eluted 
with Talianidis elution buffer at 65°C for 10 min. Crosslinking reversal of the supernatant and 
input-sample was achieved by adjusting to 0.2 M NaCl and incubation at 65°C for 5 h. 
Purification of DNA was performed using the NucleoSpin® Gel and PCR Clean-up kit according to 
the manufacturer’s protocol. Promoter binding was finally analyzed with quantitative real-time 
PCR using IgG-IP as a negative control and input-sample for quantification. In order to identify 
and quantify the DNA fragments of the respective promoter regions obtained by ChIP, primers 
were designed based on TEAD4 binding sites predicted by the JASPAR database (74). 
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4.5.3 Competitor Assay 
A competitor assay was performed to analyze the target gene dependency of tumor cells with 
regards to survival and cell proliferation. The CRISPR/Cas (Clustered Regularly Interspaced Short 
Palindromic Repeats/CRISPR-associated) system was employed to abolish target gene 
expression and cell survival was monitored using an immunofluorescence approach. Therefore, 
HepG2-Cas9 and HepG2 cells were seeded on 24-well plates as described in section 4.1.2. The 
following morning, cells were transfected with empty CRISPR-plasmids or vectors coding for a 
single-guide RNA (sgRNA). For each well, 200 ng plasmid was mixed with 1 μL Fugene® HD 
transfection reagent in 10 μL Opti-MEM. After incubation for 15 min, the transfection solution 
was spread onto the cells and medium was exchanged 5 h later. One day after transfection, 
medium was changed to RPMI medium supplemented with Puromycin (0.2 µg/mL).  
Immunofluorescence pictures were taken at days 2, 3 and 4 after transfection. For each picture, 
the green fluorescent area was measured using Fiji (75) as a surrogate marker for viability and 
transfection efficiency. 
4.5.4 Dual-Luciferase Reporter Gene Assay 
Luciferase gene reporter assay was performed to quantify the regulation of target gene 
expression. Different MCM promoter constructs were used, containing 0.6 -2 kbp of the 
promoter sequence identified by ChIP and fused to the firefly luciferase gene as described in 
section 4.3.1. Cells were seeded into 24-well plates in the morning and transfected the same 
afternoon. For transfection, 400 ng of the promoter-firefly construct was mixed with 8 ng of 
Renilla Luciferase (pRL_TK) and 2 μL of Fugene® HD transfection reagent in 50 μL Opti-MEM and 
incubated for 15 min. The transfection solution was spread onto the cells and incubated 
overnight. Transfection with siRNA was carried out directly after the medium change as 
described in section 4.1.3. Briefly, 0.5 µl of siRNAs (final concentration 40 nM) and 1.25 µL of 
Oligofectamin were diluted in Opti-MEM, then mixed and incubated at room temperature for 
15 min. Meanwhile, cells were washed with PBS, covered with 200 µL Opti-MEM/well and 
supplemented with the transfection solution. Twenty-four hours after transfection the medium 
was changed. Luciferase activity was measured 48 h after siRNA transfection using the Dual-
Luciferase® Reporter Assay System according to the manufacturer’s instructions. Therefore, 
lysates were transferred into dark 96-well plates (NuncTM) and activity was measured using a 
microplate reader (FLUOstar Omega). Firefly luciferase activity was normalized to Renilla 
luciferase activity. 
4.5.5 Expression Profiling 
Identification of differentially regulated genes was assessed by microarray analysis using the 
Clariom™ D Pico Assay (human) in cooperation with the Medical Research Center of the Medical 
Faculty Mannheim. Total RNA was isolated from HepG2 cells 48 h after RNAi treatment against 
YAP, EZH2, and SUZ12, as described in detail in sections 4.3.5 and 4.1.3, respectively. Gene 
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expression profiling was performed according to the manufacturer’s instruction in collaboration 
with the laboratory of Prof. Norbert Gretz (Med. Fakultät Mannheim). Briefly, RNA was reverse 
transcribed and then Biotin-labeled and hybridized using a GeneChip Hybridization oven 640. A 
GeneChip Fluidics Station 450 was used for staining and the microarray scanned with a 
GeneChip Scanner 3000 (Affymetrix). Arrays were annotated by Custom CDF with Entrez-based 
gene definitions (76). Raw fluorescence intensity values were normalized by quantile 
normalization and false discovery rate (FDR) correction performed using the software package 
SAS JMP7 Genomics. A false-positive rate of 0.05 was taken as the level of significance. 
Heatmaps were generated using the pheatmap package of 
R (http://CRAN.R-project.org/package=pheatmap).  
4.5.6 Cell Viability Assay 
The active reduction of resazurin to resorufin by mitochondrial enzymes is used to determine 
cell viability. Therefore, cells were seeded in 6-well plates and treated with siRNAs against 
MCMs as described in section 4.1.3. 48 h after siRNA treatment, media was replaced by 1 mL 
fresh medium containing 10% Resazurin. After incubating for 1 h at 37°C, the supernatant was 
transferred on a 96 well plate and the absorbance at 573nm (resorufin) was measured using a 
microplate reader (FLUOstar Omega).  
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5 Results 
5.1 Gene Families Regulated by the Hippo Pathway Effectors YAP and TAZ  
5.1.1 Identification of Potential YAP and TAZ Target Gene Families 
Physiologically, the Hippo pathway is crucial for controlling proliferation and apoptosis (77). It 
has been shown that deregulation of the pathway and overexpression of the co-transcriptional 
regulator YAP leads to drastic tissue overgrowth and tumor formation in vivo (58). Several 
distinct genes regulated by the Hippo signaling pathway have already been identified. However, 
it is unclear to which extent the transcriptional co-regulator YAP and its paralog TAZ affect the 
expression of functionally related gene/protein families. 
To identify groups of YAP- and/or TAZ-regulated and functionally related gene families in liver 
cancer cells, both transcriptional regulators were transiently and individually repressed by two 
independent siRNAs in HepG2 cells. In addition, YAP- and TAZ-specific siRNAs were combined to 
jointly silence both factors. Untreated and nonsense siRNA (NTC)-transfected cells served as 
controls (20 µM and 40 µM siRNA for single and combined siRNA transfection, respectively). 
Expression profiling analysis using the Affymetrix platform was performed on mRNA, which was 
isolated 48 h after siRNA transfection. The workflow in Figure 5A summarizes the steps leading 
to the identification of Hippo pathway target genes, which were further analyzed in this study. 
In total, 409 genes were consistently and significantly regulated by either both YAP siRNAs, both 
TAZ siRNAs or both combinations compared to the respective nonsense control. 163 of these 
genes were significantly downregulated and of these 13 genes were selected for further 
validation. Five of these genes were consistently downregulated upon YAP and/or TAZ silencing, 
namely ajuba LIM protein (AJUBA), DLC1 Rho GTPase activating protein (DLC1), MCM2, septin 
10 (SEPTIN10) and Suppressor Of Zeste 12 Protein Homolog (SUZ12). As already described in 
previous work of the group this approach is valid and gave reproducible results. 
Since the goal of this study was to identify groups and families of YAP/TAZ-regulated genes, 
which may cooperate in the regulation of HCC cell biology, literature describing these five genes 
was systematically screened for gene families. One identified gene frequently associated with 
proliferation and cell cycle progression was MCM2, which assembles with MCM3-7 to form a 
ring-shaped hexameric complex, named the MCM helicase (78). Because deregulation of this 
complex might facilitate tumor growth, it was tempting to test whether the expression of MCM 
family members MCM2-7 are equally regulated by YAP and/or TAZ in HCC cells. Another gene 
involved in epigenetic regulation and important for embryonic development and proliferation is 
SUZ12, a component of the polycomb repressive complex 2 (PRC2) (79). Since epigenetic 
alterations might influence gene expression in carcinogenesis, PRC2 components were also 
chosen for further analysis of transcriptional regulation by YAP and/or TAZ.  
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Figure 5: The transcriptional co-activators YAP and TAZ regulate target gene expression in vitro. 
(A) Scheme depicting YAP/TAZ – target gene selection based on gene expression array analysis. (B) Transient transfection of two 
independent YAP (#1Y, #2Y) and TAZ (#2T, #3T)-specific siRNAs alone and in combination (#1YT, #2YT) reduced respective mRNA 
expression levels measured by real-time PCR. Mean ± SD of three independent experiments in HepG2 cells is shown and 
untreated (Ø) and nonsense siRNA-transfected cells with corresponding siRNA amounts, 20 or 40 nM respectively (NTC20, 
NTC40). Data were normalized to NTC20 control values. 
In order to confirm whether the expression of these two families was affected by the Hippo 
pathway, the siRNA inhibition experiments were repeated using different liver cancer cell lines 
(Sk-Hep1, HLF, HepG2). Accordingly, the mRNA expression has been tested for six MCM genes 
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(MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7) and six PRC2 core-component genes 
(embryonic ectoderm development (EED), enhancer of zeste 1 polycomb repressive complex 2 
subunit (EZH1), enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), RB binding 
protein 4, chromatin remodeling factor (RBBP4), RB binding protein 7, chromatin remodeling 
factor (RBBP7), and SUZ12 polycomb repressive complex 2 subunit (SUZ12) following YAP/TAZ 
depletion (Figure 5B). 
Efficient knockdown of YAP at the mRNA level to less than 20% led to a reduced expression of all 
analyzed MCM mRNAs. MCM mRNA levels were homogeneously reduced to 60-75% upon YAP 
inhibition with the weakest effects on MCM6 and the strongest effects on MCM2 expression in 
HepG2. In contrast, the efficient TAZ inhibition to about 30% alone led to no consistent change 
on MCM mRNA levels, with a remaining MCM6 mRNA abundance of 80-90% being the strongest 
observed reduction. Interestingly, the combined inhibition of YAP and TAZ reduced MCM4 
mRNA amounts to 45-50% as compared to single YAP inhibition (58-68%), whereas MCM7 was 
reduced to about 60% for both treatments. Additionally, single YAP inhibition in Sk-Hep1 cells 
reduced all MCM mRNA levels as low as 45-85% (MCM7 and MCM6; data not shown). 
Furthermore, combined YAP and TAZ inhibition led to consistently diminished MCM expression 
to 20% for MCM7 and 40% for MCM3. Moreover in HLF cells, combined reduction of YAP and 
TAZ to below 20% and 40%, respectively, decreased MCM2-7 abundance to 30-80% (datanot 
shown). Thus the combined inhibitions had in most cases either comparable or enhanced 
effects as compared to single inhibition, which indicated that YAP and TAZ cooperate in the 
transcriptional regulation of MCMs. For this reason, all further experiments concerning MCM 
helicase were conducted using combined YAP and TAZ inhibition.  
As indicated by the expression array data, some PRC2 components were reduced upon efficient 
YAP knockdown. SUZ12 showed the most prominent effects, with a reduction to approximately 
55% following YAP reduction, whereas EZH1 abundance was not drastically affected in HepG2 
cells. In contrast, TAZ inhibition neither had reproducible effects on PRC2 components when 
silenced individually nor any additional effects in combination with YAP. Similar effects were 
observed in Sk-Hep1 cells, showing a reduced mRNA expression of EED, EZH2, SUZ12 and 
RBBP4/7 to 50-80% upon single YAP and combined YAP/TAZ inhibition. These results pointed to 
an exclusive regulatory role of YAP on PRC2 constituents. Therefore, all further experiments 
focusing on PRC2 factors were conducted after single YAP inhibition.  
Taken together, these results show that mRNA expression of MCM helicase family members and 
PRC2 complex components were positively regulated by the Hippo pathway effectors YAP 
(MCMs and PRC2 complex) and TAZ (MCMs) in liver cancer cells (HLF, HepG2, Sk-Hep1). In the 
following, this study focuses first on the effects of YAP and TAZ on MCM expression and later on 
the regulation of PRC2 by YAP.  
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5.2 MCM Protein Family 
5.2.1 YAP and TAZ Regulate MCM Expression via TEAD 
Pursuing the previous findings, showing that YAP and TAZ knockdown reduced MCM mRNA 
expression, immunoblotting analysis was performed. Therefore, different liver cancer cell lines 
were treated with a combination of YAP and TAZ-specific siRNAs for 48 h (HLF, HepG2, Sk-
Hep1). Efficient combined YAP and TAZ knockdown was associated with reduced protein 
abundance of MCM2-7 as shown exemplary for HLF cells in Figure 6. YAP and TAZ knockdown to 
about 5% and 30% respectively, reduced MCM6 protein levels to 60-65% and MCM4 protein 
levels to 50-70%. Although MCM5 and MCM7 abundance decreased moderately to 80-95%, the 
effects on MCM2 and MCM3 with a reduction to 50-80% and 70-80%, respectively, were more 
diverse but consistent. Similar changes in protein abundance were observed in HepG2 cells and 
by 10-20% enhanced in Sk-Hep1 cells. 
 
Figure 6: The transcriptional co-activators YAP and TAZ regulate MCM gene expression in vitro. 
(A) Transient transfection with two YAP and TAZ-specific siRNAs led to reduced levels of MCM proteins as exemplarily illustrated 
by Western Blot analysis in HLF cells. Untreated (Ø) and nonsense siRNA (NTC) transfection served as controls. GAPDH was used 
as a loading control. (B) Protein quantification of MCM proteins relative to GAPDH expression of two independent experiments. 
Comparable results were achieved for Sk-Hep1 and HepG2 cells (not shown). 
The Hippo pathway effectors YAP and TAZ are transcriptional coactivators lacking a DNA binding 
site (80). Indeed, several transcription factors have been reported to interact with YAP and TAZ 
to regulate the transcription of different target genes. A well-described protein group of 
YAP/TAZ-binding transcription factors is the TEAD-family, consisting of four family members 
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(TEAD1-4) (34). In order to assess whether these transcription factors are also involved in the 
regulation of MCM expression, TEAD family members were inhibited by RNAi in liver cancer cell 
lines (Sk-Hep1, HLF). Initial data showed expression of TEAD2 and TEAD3 only at low levels in 
the used cell lines (data not shown). Therefore, a combined siRNA-mediated knockdown of 
TEAD1 and TEAD4 expression was performed. Figure 7A illustrates the reduced mRNA 
expression of TEAD1, TEAD4, and all MCM family members in Sk-Hep1 cells. The strongest 
effects were observed on MCM2 and MCM7 mRNA levels upon combined TEAD1 and TEAD4 
inhibition with a reduction to 25-40% and 20-30%, respectively. In sum, a reduction of TEAD1/4 
mRNAs below 20% was accompanied by a reduction of MCM2-7 mRNA by 50 to 80%. 
 
Figure 7: Verteporfin and the transcription factors TEAD1 and TEAD4 regulate MCM gene expression in vitro. 
(A) Transient transfection of two TEAD1 and TEAD4-specific siRNAs reduced expression levels of MCM genes, as illustrated by 
real-time PCR. Mean±SD of two independent experiments in Sk-Hep1 cells is shown. Untreated (Ø) and nonsense siRNA (NTC) 
transfected cells served as controls. Data were normalized to NTC controls. Comparable results were achieved for HLF cells (not 
shown). (B)  Treatment with Verteporfin for 48 hours reduced MCM protein levels in HLF cells. Untreated (Ø) and DMSO-treated 
cells served as controls. β-Actin was used as a loading control. (C) Quantification of MCM proteins relative to Actin expression of 
two independent experiments. Comparable results were achieved for Sk-Hep1 and HepG2 cells (not shown). 
These data strongly suggested partial YAP/TAZ/TEAD-dependency of MCM protein expression in 
liver cancer cells. To substantiate this mechanistic connection, the FDA-approved substance 
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Verteporfin was administered to HCC cells. This drug is a photosensitizer used to treat macular 
degeneration but has also sensitizer-independent properties, including the inhibition of the 
YAP/TAZ/TEAD interaction followed by YAP/TAZ degradation (81). 
Quantitative immunoblotting analysis of Verteporfin-treated HLF cells is displayed in Figure 7BC 
showing a clear gradual decrease of MCM6 and MCM7 protein level with increasing drug 
concentration compared to the respective controls. For MCM2-5, a moderate protein reduction 
was detectable. However, the simultaneous decrease of the house-keeper β-Actin complicated 
the analysis of these MCM family members at the protein level. Nevertheless, these data 
further supported the YAP- and TEAD-dependent transcriptional regulation of MCMs in liver 
cancer cells. 
To further confirm the physical interaction of YAP/TAZ and TEAD4 with the promoter regions of 
the MCM genes, additional ChIP and luciferase assays experiments were performed. Therefore, 
the gene promoter sequences of all MCM family genes (defined as -2 kbp to +1 kbp) were 
analyzed using the software JASPAR to predict possible TEAD4 binding sites. Various potential 
TEAD4 binding sites were detected and scored by the binding probability, with a score of 5-8 
representing medium binding probability. Within the predicted binding sites scored higher 
than 8, primer pairs were designed around the potential binding sites closest to the 
transcription starting site (PCR product smaller than 200 bp). The ChIP-primer pairs surrounding 
the predicted TEAD4 binding sites were validated on total genomic DNA and shown in Figure 8A. 
Within the MCM4 promoter region, no suitable primer pair could be found due to the GC-rich 
character of this genomic region. 
The real-time PCR analysis of DNA precipitated from HLF cells is shown in Figure 8 B, illustrating 
the specific binding of YAP, TAZ, and TEAD4 to the predicted MCM promoter regions (with 
exception of MCM4). TEAD4-ChIPs showed higher amounts of precipitated DNA compared to 
YAP-ChIP and TAZ-ChIP due to the indirect binding of YAP and TAZ to DNA. Following YAP-IP, 
0.16% to 0.34% of input DNA covering analyzed MCM3 and MCM6 promotor regions were 
precipitated, respectively. Similar, but partly weaker effects could be observed upon TAZ-IP with 
0.05% (MCM5) to 0.32% (MCM3) of precipitated input-DNA. TEAD4-IP bound almost twice the 
amount of DNA with 0.23% for MCM5 and 0.56% for MCM3. ChIP analysis in HepG2 cell 
confirmed these findings and showed a reproducible precipitation of 0.4% (MCM2) to 1.8% 
(MCM3) of all MCM promoter regions upon TEAD4-IP. These results confirmed the direct 
interaction of YAP, TAZ with TEAD4 to the predicted binding sites within the MCM gene 
promoter regions. 
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Figure 8: YAP, TAZ, and TEAD4 physically bind to MCM gene promoters.  
(A) Schemes illustrate promoter regions fused to Firefly luciferase for luciferase assays with TEAD4 binding sites targeted by ChIP 
assay-primers (location indicated by arrows). (B) ChIP with YAP, TAZ, TEAD4 and IgG control confirmed binding to the predicted 
promoter positions in HLF. Similar results were obtained for HepG2 cells (not shown). IP = Immunoprecipitation. (C) Combined 
siRNA-inhibition of YAP and TAZ reduced MCM promoter activity measured by Firefly luciferase activity normalized to Renilla 
luciferase activity. Untreated (Ø) and nonsense siRNA (NTC) transfection served as controls. Mean±SD of three independent 
experiments in HLF cells is shown. Comparable results were achieved for HepG2 cells.  
To verify the functional relevance of YAP and TAZ on MCM expression in HLF cells, luciferase 
assays were performed using plasmids containing MCM promoter regions. Therefore the 
respective promoter regions, containing the TEAD4 binding sites, which were shown in the 
previous ChIP assays, were cloned upstream of a plasmid-based Firefly luciferase gene (Figure 
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8A). Due to technical problems in cloning, only vector constructs for MCM2-4 and 6-7 
promoters have been generated and verified by sequencing. The Firefly luciferase constructs 
were transiently co-transfected into HepG2 and HLF cells with a Renilla luciferase plasmid used 
for normalization 8 h prior to siRNA treatment. Luciferase activity was measured 48 h after 
plasmid transfection. The normalized luminescence intensities illustrated an obvious reduction 
for the MCM3, MCM6, and MCM7 reporters after YAP/TAZ inhibition (between 10 and 40%; 
Figure 8C). For MCM2 and MCM4, one siRNA combination showed a reproducible signal 
decrease, while the other combination led to a moderate (for MCM2, second siRNA 
combination) or no (for MCM4, second siRNA combination) reduction of Luciferase activity 
compared to the controls. 
In summary, expression data analysis after genetic manipulation and treatment with a 
YAP/TAZ/TEAD inhibitor, protein binding studies as well as activity assays illustrate that both 
Hippo pathway effectors YAP and TAZ directly regulate the transcription of MCM helicase genes 
in different liver cancer cell lines in a TEAD-dependent manner. 
5.2.2 YAP Regulates MCM mRNA Expression in vivo 
Following up on the above demonstrated regulation of MCMs by YAP in vitro, a transgenic 
mouse model with inducible and hepatocyte-specific overexpression of constitutively active 
human YAPS127A was employed (Figure 9A)(50). In this model, the liver activator protein (LAP) is 
controlling the tetracycline transactivator (tTA) expression. The tTA protein is interacting with 
doxycycline, which is administered with the drinking water, leading to its inactivation (TET-off 
system). Upon doxycycline withdrawal, the tTA activates the tetracycline-inducible promoter, 
controlling the expression of the mutant YAPS127A gene. After 8 – 12 weeks of YAPS127A 
overexpression, mice develop a severe increase in liver size (hepatomegaly, 8 weeks) and 
eventually tumor formation (12 weeks), with exemplary livers shown in Figure 9B. 
 
Figure 9: Confirmation of YAP-dependent MCM expression in a transgenic mouse model. 
(A) Illustration of liver-specific and doxycycline-dependent YAP
S127A
 overexpression as described by Camargo (50). The liver 
activator protein (LAP) promoter controlling the expression of tetracycline transactivator (tTA) ensures tissue-specificity. The 
mutant YAP gene expression is regulated by a Tet-promoter located downstream of the collagen type I alpha 1 chain locus 
(Col1A1). (B) Withdrawal of doxycyclin induces the hepatocyte-specific expression of the mutant YAP gene (YAP
S127A
). Induction 
of the transgene for 8 - 12 weeks increased the liver size and first macroscopic tumors are detectable. (C) Expression levels of 
YAP and murine MCM2-7 mRNAs were analyzed in livers of wildtype (WT; 5 mice) and YAPtg mice after 8 and 12 weeks (5 and 4 
mice respectively) of YAP
S127A
 induction. (* p < 0.05; ** p < 0.01; *** p < 0.001) 
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The mRNA levels of all murine MCM family members in transgenic mouse livers after 8 (without 
macroscopic tumors; n = 5) or 12 (with macroscopic tumors; n = 4) weeks of transgene induction 
was compared with wildtype mouse livers (n = 5). Real-time PCR analysis revealed 2 to 5-fold 
elevated MCM2-7 expression levels upon YAPS127A induction (Figure 9C). Tumor-bearing mice 
had significantly higher MCM3, MCM5, MCM6, and MCM7 expression levels after 12 weeks of 
doxycycline-withdrawal. Importantly, 8 weeks after YAPS127A overexpression (malignant 
transformation), transgenic mouse livers already showed a 3 to 5-fold increase of MCM4, 
MCM5, MCM6, and MCM7 mRNA levels compared to the control group.  
In summary, these results further illustrate that elevated MCM2-7 levels are regulated by YAP in 
primary murine hepatocytes. Importantly, this MCM overexpression is already detectable in 
pre-malignant livers, illustrating that these elevated MCM amounts are not due to malignant 
transformation.  
5.2.3 MCM Family Members Regulate HCC Cell Proliferation  
To assess the relevance of the MCM family members in HCC cells, different functional assays 
were performed. For this purpose, siRNA inhibitions for individual MCM family members were 
established (exemplary immunoblots shown in Figure 10A). Efficient reduction was confirmed at 
the protein levels with a reduction of individual MCMs below 25%. Cell viability assays were 
performed 48 h after siRNA treatment in Sk-Hep1 and HepG2. Targeting different MCMs, no 
consistent or reproducible reduction of cell viability could be observed, as exemplary shown for 
MCM2, MCM6 and MCM7 (Figure 10B). 
 
Figure 10: Individual MCM inhibition has no influence on cell viability.  
(A) Transient knockdown of MCM2, MCM6 or MCM7 with specific siRNAs led to reduced protein levels of the respective MCMs 
after 48h, as illustrated by Western Blot analysis in HepG2 and Sk-Hep1 cells. (B) Cell viability-assay: Transient knockdown of 
MCM2, MCM6 or MCM7 had no consistent effect on cell-viability after 48h of inhibition. Untreated (Ø) and nonsense siRNA 
(NTC) transfection served as controls. Mean±SD of two independent experiments in HepG2 and Sk-Hep1 cells is shown. 
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It was hypothesized that the lack of change in cell viability was either due to a low sensitivity of 
the applied test or the residual amount of the respective amount was sufficient to ensure DNA 
replication. In order to overcome these obstacles, one approach was to totally delete MCMs 
employing the CRISPR/Cas9 system.  
Therefore, plasmids were cloned that contained GFP, a single guide RNA (sgRNA) targeting 
MCM2 and the pac gene, encoding N-acetyl-transferase for puromycin-resistance. HepG2 cells 
stably expressing Cas9 (HepG2-Cas9) were generated and transfected, but no homozygous 
MCM2-deleted stable cells could be obtained. This led to the conclusion, that complete 
silencing of MCM2 is essential for proliferation. To further define the temporal impact of MCM2 
on cell viability a competitor assay was established as illustrated in Figure 11A.  
 
Figure 11: Competitor assay. 
(A) Scheme illustrating CRISPR/Cas9-based competitor assay and enzymes and RNA present in successfully transfected cells. (B) 
Anticipated course of the experiment with effectively transfected cells expressing GFP in gray and untransfected cells in white. 
(C) Competitor assay: Transfection of HepG2 and HepG2-Cas9 cells, with sgRNA-coding or empty CRISPR-plasmids. The green 
fluorescent area was measured and normalized to day 2 and the mean of 3 independent experiments is depicted in the graph.   
Therefore, HepG2-Cas9 cells were transfected with the plasmid coding for the sgRNA targeting 
MCM2, selected with puromycin and immunofluorescene pictures were taken. HepG2 cells 
transfected with the MCM2 targeting vector (Control-1) and HepG2-Cas9 cells transfected with 
an empty vector (Control-2) served as controls (Figure 11B). The green fluorescent area 
represented an indicator for the number of cells with sgRNA-mediated MCM2 inhibition 
(MCM2) or transfected cells with intact MCM2 (Control-1 and Control-2). The GFP-positive area 
per picture was measured and normalized to the data obtained at day two after transfection. 
Therefore, in this assay the GFP-positive area could be associated with the amount of cell 
proliferation and the cumulative result of three independent experiments illustrated in Figure 
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11C. The results showed a steady increase of green areas (proliferating cells) in both control 
groups on day 3 and 4. On the contrary, cells lacking MCM2 (HepG2-Cas9 sgMCM2) showed 
reduced proliferation 4 days after transfection. 
Another approach to investigate the impact of MCMs on liver cancer cell proliferation was to 
reduce the protein expression of all MCM family members (MCM2-7) at once. It was assumed 
that the combined RNAi treatment would reduce the stochastic probability of individual cells 
expressing all MCM proteins and thus masking possible effects. Therefore, combined siRNA 
inhibitions combining all siRNAs that target all MCM family members were established and a 
reduction of each MCM within a single treatment to below 25% was considered as efficient 
(Figure 12AB).  
 
Figure 12: YAP and TAZ influence proliferation via MCM regulation. 
(A) Transient knockdown of YAP/TAZ and all MCM family members with specific siRNAs led to reduced protein levels of the 
respective proteins as illustrated by Western Blot analysis in HLF cells. GAPDH was used as a loading control. (B) Quantification 
of two independent experiments as described in (A) normalized to GAPDH expression. Comparable results were achieved for 
HepG2 cells (not shown). (C) BrdU-assay: Transient knockdown of YAP/TAZ and all MCMs led to reduced BrdU incorporated into 
genomic DNA, 48 hours after inhibition. Untreated (Ø) and nonsense siRNA (NTC) transfection served as controls. Mean±SD of 
three independent experiments in HLF cells is shown. Comparable results were achieved for HepG2 cells (not shown).  
The relevance of all MCM family members on proliferation was examined using a BrdU assay 
after combined siRNA-mediated silencing of all MCMs in HepG2 and HLF cells. Inhibition of YAP 
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and TAZ was performed as a positive control. The thymidine analog BrdU was subjected to the 
medium 48 h after RNAi treatment for 1 h of incubation, and incorporated by proliferating cells 
stochastically into duplicating DNA. Efficient, combined MCM2-7 knockdown has similar effects 
as combined YAP and TAZ knockdown on BrdU incorporation in HLF cells. In total, the BrdU-
incorporation assay illustrated that proliferation is reduced about 20-40% after MCM2-7, YAP 
and TAZ knockdown in HepG2 and HLF cells (Figure 12C and data not shown) confirmed that 
efficient, combined MCM2-7 knockdown has similar effects as YAP and TAZ. 
Taken together, these results demonstrate that only the efficient and rapid knockdown of 
MCM-helicase in liver cancer cell lines leads to reduced cell proliferation visible in BrdU ELISA 
assay. The more sensitive assay confirmed the pro-proliferative role of an individual MCM (here 
MCM2) in cell proliferation (competitor assay).  
5.2.4 MCM2-7 Expression Correlates to Poor Clinical Prognosis in Human HCC 
The previous results demonstrated that YAP positively correlated with MCM2-7 expression, in 
vitro and in vivo, and that YAP/TAZ directly regulated MCM transcription. In order to validate 
these findings in independent human HCC cohorts, mRNA expression data derived from 242 
HCC patients (cohort 1) (72) and 370 liver cancer patients (cohort 2) (27) were analyzed. The 
comparison of mRNA levels in tumor with the corresponding non-tumorous liver tissue showed 
that all MCM helicase components were significantly overexpressed in HCC tissues (Figure 13). 
 
Figure 13: Elevated expression of MCMs in human HCCs. 
MCM2-7 mRNA is overexpressed in a cohort of 242 liver cancer patients compared to surrounding liver tissue (cohort 1). 
(*** p < 0.001) 
To correlate the amounts of individual MCM mRNA levels with clinical outcome of HCC patients, 
Kaplan-Meier plots were generated. Therefore, data from HCC patients were divided into equal 
groups (threshold: median) according to their MCM2-7 mRNA expression levels. HCC patients 
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with higher MCM helicase expression had significantly worse overall survival and earlier cancer 
recurrence as compared to patients with lower MCM expression (Figure 14). 
In order to determine whether clinicopathological features were associated with the general 
expression of all MCM helicase family members in HCC patients (cohort 2), the individual MCM 
mRNA expression data were combined and summed up to a score. The MCM score was then 
used to divide the patients into three groups of high (34%), medium (33%) and low (33%) 
helicase expression. Patient characteristics including age and tumor grading were analyzed with 
respect to the MCM classification and the numbers of patients with a certain characteristic were 
quantified. Data analysis revealed no significant enrichment of female or male patients in 
groups with high-medium, or low MCM expression scores (Table 32).  
 
Figure 14: Elevated expression of MCMs correlates with poor prognosis in HCC patients.  
Kaplan-Meier analysis of MCM2-7 for overall and recurrence-free survival in cohort 1 with blue indicating high and red low 
expression levels. High MCM transcript levels significantly correlate with earlier tumor recurrence and disease-free survival 
(Wilcoxon-test). Comparable results were achieved for the TCGA LIHC cohort (not shown). (* p < 0.05; ** p < 0.01; 
*** p < 0.001) 
Furthermore, the age of patients, vascular invasion, and inflammation did not statistically 
correlate with the amount of MCMs mRNA levels in this cohort. Asian and Caucasian patients 
were equally represented in the dataset. However, the Caucasian patients were significantly 
enriched in the group with low MCM abundance. In addition, the parameter 'family history', 
which represents cancer diagnosis of genetically related family members, was significantly 
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associated with a higher expression of MCM helicases. Patients with a high body mass index 
(BMI >30) were significantly overrepresented within the low MCM patient cluster. In agreement 
with the analyzed survival data, TNM stage and tumor grade at diagnosis significantly correlated 
with higher MCM expression. 
Together, these findings indicate that all MCM helicase family members are overexpressed at 
mRNA level in human HCC and that elevated MCM2-7 expression is associated with tumor 
dedifferentiation and poor clinical outcome of HCC patients. 
Table 32: Elevated expression of MCMs correlate with clinicopathological features. 
An MCM score was used to divide patients into groups with high, medium and low MCM expression, by summing the mRNA 
expression values for MCM2-7 in cohort2. Additionally, patients were divided into groups for each feature, followed by the 
quantification of the number of patients in each group. The median value was used to assign for the analysis of age. The 
numbers of patients with the respective clinicopathological feature are listed in the table together with the p-value of the 
statistical test (Chi-squared test). n.s.=not significant  
  
5.2.5 YAP Expression Correlates to MCM Expression in Human HCC 
To further confirm the overexpression of individual MCMs on protein levels and to associate 
their abundance with the subcellular localization of YAP in tumor cells, immunohistochemical 
stains of TMA containing 105 HCCs and 7 normal liver tissues were performed.  
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Figure 15: YAP expression correlates with MCM-helicase expression and histological grading in HCC patients. 
(A) TMA evaluation shows a significant correlation between YAP and MCM2-7 levels with tumor gradings (G1-G4) as illustrated 
by the bar graph. G0 = healthy liver. (B) Exemplary immunohistochemical stains of YAP and Ki67 positive human HCC tissue 
stained for Ki67, YAP and MCM2-7, respectively. 
 
 
 
Figure 16: YAP and Ki67 negative human HCC samples (TMA analysis). 
Exemplary immunohistochemical stain of YAP and Ki67 negative human HCC tissue stained for Ki67, YAP and MCM2-7. 
For this purpose, respective staining protocols for YAP, the proliferation marker KI67, and 
MCM2-7 were established. Systematic evaluation of all TMAs revealed a strong correlation of 
YAP and MCM2-7 protein expression with tumor grading, which further validated the previous 
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findings of the expression analysis (Figure 15A; Table 33). Exemplary stains for YAP and Ki67 
double positive and negative HCC tissues are shown in Figure 15B and Figure 16, respectively. 
Hence MCMs are functionally related proteins, comparable protein staining levels in individual 
HCC tissue samples were expected. Indeed, statistical comparison of MCM stains revealed a 
highly significant and positive correlation of MCMs with each other (Table 33). 
As expected from the literature, Spearman analysis of TMA evaluation showed a significant 
correlation of nuclear YAP expression with the proliferation marker Ki67 (61). In addition, YAP 
and Ki67 showed a significant positive association with all MCM helicase members in HCC 
tissues (Table 33).  
Table 33: YAP and Ki67 expression correlate with MCM2-7 expression and histological grading in HCC patients. 
Spearman correlation analysis of evaluated TMAs illustrates a significant correlation between YAP and Ki67 with MCM2-7 levels 
and tumor gradings (G). (* p < 0.1; ** p < 0.01). 
  
To further support the association of Hippo pathway effectors and MCM family members, 
Spearman analysis of the mRNA expression data in cohort 2 has been performed (Table 34). As 
expected from the TMA analysis, YAP mRNA expression significantly correlated with the mRNA 
expression of all MCM family members. Moreover, a moderate but significant correlation of the 
two Hippo effectors YAP and TAZ with each other became apparent in cohort 2. In line with this 
observation, TAZ expression showed moderate correlation to MCM3, MCM5, MCM6, and 
MCM7 and no significant correlation to MCM2 and MCM4 expression.  
Together, these findings show that all MCM helicase family members correlate strongly with 
YAP, Ki67 and moderately with TAZ expression in human HCC. Additionally, elevated MCM2-7 
levels are associated with high tumor dedifferentiation. 
Table 34: YAP and TAZ mRNA expression correlate with MCM helicase mRNA expression in human HCC. 
(cohort2; * p < 0.1; ** p < 0.01). 
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5.3 PRC2 
5.3.1 YAP Regulates PRC2 Component Expression via TEAD 
Because in the initial screen, some PRC2 complex family members were differentially regulated 
after YAP inhibition (Figure 5), the impact of YAP on these factors was further investigated in the 
second part of the project. In order to confirm the positive regulatory effects of YAP on PRC2 
components in section 5.1.1, immunoblot analysis was performed after YAP silencing in liver 
cancer cells. Therefore, HepG2, Sk-Hep1 and HLF cells were transfected with two YAP-specific 
siRNA for 48 h and the protein expression was analyzed (Exemplary shown for HLF cells in Figure 
17. Due to weak effects of YAP inhibition on mRNA expression, EZH1 was excluded from further 
analyses. In addition, and due to limited antibody availability, RBBP4 and EED protein expression 
could not be further analyzed. However, for the remaining factors (EZH2, SUZ12 and RBBP7), 
immunoblot quantification showed that efficient YAP knockdown was associated with reduced 
PRC2 protein expression in HLF cells. 
 
Figure 17: The transcriptional co-activator YAP regulates PRC2 component expression in vitro. 
(A) Transient transfection with YAP-specific siRNAs led to reduced levels of EZH2, SUZ12 and RBBP7 proteins as exemplarily 
illustrated by Western Blot analysis in HLF cells. (B) Protein quantification of PRC2 components relative to GAPDH expression of 
two independent experiments. Untreated (Ø) and nonsense siRNA (NTC) transfection served as controls. GAPDH was used as a 
loading control. Comparable results were achieved for Sk-Hep1 and HepG2 cells (not shown). 
As for the MCMs, the involved transcription factor interacting with YAP and regulating PRC2 
components had to be identified. For this, Sk-Hep1 cells were treated with TEAD1 and TEAD4-
specific siRNA for 48 h and analyzed via real-time PCR. Figure 18A shows that a reduction of 
TEAD mRNA to 10-20% led to a reduction of the analyzed PRC2 components by 25 to 75% at the 
mRNA level in Sk-Hep1, suggesting that these TEAD family members are involved in the YAP-
dependent regulation of EZH2, SU12, RBBP7.  
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To further analyze the YAP/TEAD-dependency of the PRC2 protein expression, HLF and HepG2 
cells were treated with different concentrations of the YAP/TEAD inhibitor Verteporfin. Even 
though a decreased expression of EZH2, SUZ12, and RBBP7 by 10 to 40% compared to the 
DMSO-control was detected when treated with Verteporfin, no dose dependent change in 
protein abundance could be observed (Figure 18BC). Hence mRNA analysis of Verteporfin 
treated HepG2 and Sk-Hep1 cells showed a gradually decreased expression of EZH2, SUZ12 and 
RBBP7 to 20-40% (data not shown). This data further support the relevance of the YAP/TEAD 
transcription complex for the regulation of the analyzed PRC2 components in HepG2 and Sk-
Hep1. 
 
Figure 18: Effects of Verteporfin and the transcription factors TEAD1 and TEAD4 on PRC2 components in vitro. 
(A) Transient transfection of two TEAD1 and TEAD4-specific siRNAs reduced expression levels of PRC2 components, as illustrated 
by real-time PCR. Mean±SD of two independent experiments in Sk-Hep1 cells is shown. Untreated (Ø) and nonsense siRNA (NTC) 
transfected cells served as controls. Data were normalized to NTC controls. (B)  Treatment with Verteporfin for 48 h reduced 
EZH2, SUZ12 and RBBP7 levels in HLF cells. Untreated (Ø) and DMSO-treated cells served as controls. β-Actin was used as a 
loading control. (C)  Quantification of PRC2 complex proteins relative to β-Actin levels of two independent experiments is 
shown. Comparable results were achieved for HepG2 cells (not shown). 
To validate these findings by ChIP, the human promoter sequences of EZH2, SUZ12, and RBBP7 
(-2 kbp until +1 kbp) were subjected to online software analysis tool JASPAR, which predicted 
various potential TEAD4 binding sites. The predicted TEAD4 binding sites with a binding score of 
8 or higher were considered for primer design. ChIP-primer pairs were designed focusing on the 
predicted binding sites closest to the transcription start of each gene (predicted PCR product 
smaller than 200 bp). The primers functionally validated on total genomic DNA are shown in 
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Figure 19A. DNA precipitated from HLF cells using TEAD4-antibody was analyzed by real-time 
PCR and shown in Figure 19B. TEAD4-ChIPs could precipitate 0.07% to 0.11% of input-DNA 
covering RBBP7 and EZH2 promoter regions respectively, whereas IgG-IP did not precipitate any 
detectable DNA. Additional ChIP analysis in HepG2 cells showed a precipitation of EZH2 and 
SUZ12 promoter regions of 0.8-0.9% input-DNA, respectively. 
 
Figure 19: TEAD4 physically binds to PRC2 gene promoters. 
(A) Schemes illustrate promoter regions fused to Firefly luciferase with TEAD4 binding sites targeted by ChIP-primers (location 
indicated by arrows). (B) ChIP with YAP, TAZ, and TEAD4 confirmed binding to the analyzed consensus sites in HLF. Similar 
results were obtained for HepG2 cells (not shown). IP = Immunoprecipitation. 
Together, these results indicate an interaction of a YAP/TEAD4 complex that directly regulates 
the transcription of PRC2 components through promoter binding in different liver cancer cell 
lines. 
5.3.2 YAP Regulates PRC2 mRNA Expression in vivo 
Having established that YAP regulates the expression of PRC2 components at the transcriptional 
level in vitro, it was intended to confirm these observations in the YAPS127A mouse model (Figure 
13A). Therefore, primary hepatocytes isolated from 6 wildtype mice were compared to YAPS127A-
positive hepatocytes isolated from 4 mice, 8 weeks after transgene induction. Real-time PCR 
analysis illustrated a 1.3-fold induction for SUZ12 and an up to 3.6-fold increase for EZH2 upon 
YAP induction (Figure 20). 
 
Figure 20: YAP-transgenic mouse model. 
Expression levels of YAP and PRC2 components mRNA (EED, EZH1, EZH2, RBBP4, RBBP7, and SUZ12) were analyzed from 
isolated hepatocytes of wildtype (WT; n=6) and YAPtg (n=4) mice after 8 weeks of YAP
S127A
 induction. (*** p < 0.001; * p < 0.05) 
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These results further illustrated that elevated levels of these PRC2 components correlated with 
YAP overexpression already in primary hepatocytes isolated from pre-malignant murine livers 
with YAP-induced hyperplasia. 
5.3.3 YAP Regulates Histone H3 Trimethylation via PRC2 Expression 
Having established that YAP directly regulates the expression of PRC2 components, the next 
step was to determine whether the biological effects of PRC2 may be influenced by YAP activity. 
PRC2 is catalysing the trimethylation of lysine 27 of histone H3 (H3K27me3), an epigenetic mark 
silencing gene transcription (82). In order to test whether the absence of YAP reduces the 
abundance of this epigenetic mark, siRNA-mediated knockdown of YAP was repeated in 
different liver cancer cell lines. Figure 21 shows a decrease of SUZ12, EZH2 and RBBP7 levels and 
a subsequent reduction of H3K27me3 by 60-80% upon YAP silencing. To ascertain if the 
observed effect is mediated by PRC2, HLF cells were treated with an EZH2-specific kinase 
inhibitor (Tazemetostat) for 48 h. Tazemetostat is intended to exclusively inhibit the 
methyltransferase activity of PRC2 without affecting protein expression (83). Compared to 
DMSO treated cells, Tazemetostat had no conclusive effects on the protein abundance of EZH2, 
SUZ12, and RBBP7 as depicted in Figure 21. On the other hand, H3K27me3 was reduced to 27% 
in HLF and 23% in HepG2 cells upon drug treatment for 48 h compared to the respective 
controls. 
 
Figure 21: Trimethylation of histone H3 regulated by YAP via PRC2. 
(A) Exemplary Immunolot displaying total histone H3 and H3K27me3 after Tazemetostat treatment and RNAi knockdown of YAP 
in HLF cells. (B) Immunoblot quantification of two independent RNAi knockdown experiments illustrating PRC2 components and 
H3K27me3 upon Tazemetostat treatment and RNAi knockdown of YAP in HLF and HepG2 cells. Untreated (Ø), DMSO and 
nonsense siRNA (NTC) transfection served as controls. GAPDH and total histone H3 were used as a loading control. 
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These findings demonstrate that the expression of the epigenetic marker H3K27me3 was 
reduced upon YAP inhibition and EZH2 kinase inhibition. 
5.3.4 Comparison of YAP and PRC2 Target Genes in HCC Cells  
The previous data indicated that YAP may regulate histone methylation via the transcriptional 
control of essential PRC2 complex constituents. However, it is unknown which negatively 
regulated YAP target genes might be affected by this molecular mechanism. A comparative 
expression profiling analysis of HCC cells was performed to define genes, which are inversely 
controlled by PRC2-histone methylation and thereby represent indirect YAP target genes. For 
this reason, YAP as well as the PRC2 constituents EZH2 and SUZ12, were inhibited by two 
independent siRNAs in HepG2 cells. Total mRNA was isolated 48 hours after inhibition and 
subjected to expression profiling analysis (Affymetrix platform). Biological replicates of HepG2 
cells transfected with two siRNAs were compared with nonsense siRNA treated cells. As 
depicted in Figure 22A, the working hypothesis for target gene analysis was that nuclear YAP 
positivity is associated with increased PRC2/H3K27me3 abundance and gene inhibition. Figure 
22B shows the workflow from the identification of significantly regulated genes in the array up 
to the identification of possibly regulated pathways and target genes using Ingenuity Pathway 
Analysis (IPA) software. 
In total, 1,311, 1,124 and 686 genes were significantly regulated by both siRNAs targeting EZH2, 
SUZ12, and YAP, respectively. The VENN diagram in Figure 22C shows that 133 of all significantly 
regulated genes (n=2,324) are coregulated by all three analyzed proteins. To narrow down the 
number of genes presumably regulated by the mechanism depicted in Figure 22A, the 
transcriptome data was filtered for significantly up-regulated genes upon YAP, SUZ12 or EZH2 
knockdown. In total, 1,147 genes were significantly and consistently elevated in these arrays 
with 5.8% (66 genes) regulated by YAP and both PRC2 complex constituents (Table 37; Table 
38). 
In the next step, regulated pathways associated with these transcriptionally modified genes 
were examined using the IPA software. Each siRNA treatment consisting of two independent 
siRNAs was analyzed separately by subjecting the whole panel of significantly regulated genes to 
IPA core analysis. Each core analysis assigns activation z-scores to each pathway, which predicts 
an association for the functional impact on a pathway. The top canonical pathways activated in 
4 out of 6 core analysis include FXR/RXR-activation (p = 4x10-4 to 9x10-14), a signalling pathway 
that is involved in several  liver specific processes as bile acid regulation and lipoprotein, lipid, 
and glucose metabolism. Additionally, acute phase response signaling is activated in 5 out of six 
core analysis (p=2x10-3 to 5x10-15), part of the early-defense system triggered by neoplasia 
amongst other stimuli and the proteins involved partly overlap with proteins in IL6- or PI3K/AKT 
signaling. These results were merged using IPA comparison analysis and the z-scores of the 20 
strongest regulated pathways (activation and inactivation) are shown in Figure 23A. This list of 
Results 
70 
 
pathways with potential impact on tumor cell biology include degradation of serotonin (z-
score = 2.6 – 2.8), TGF-β-signaling (z-score = 0.8 – 2.6) and five pathways associated with 
cholesterol metabolism, like cholesterol biosynthesis (z-score = -1.3 – -2.5) and LXR/RXR 
activation (z-score = 2.8 – 3.7). 
 
Figure 22: Transcriptome analysis upon YAP, EZH2 and SUZ12 knockdown. 
(A) Scheme depicting the working hypothesis where nuclear YAP localization increases PRC2 levels and trimethylation of H3K27 
resulting in target gene repression. (B) Scheme depicting microarray evaluation and IPA analysis. (B) VENN diagram of 
significantly (up)-regulated genes by RNAi knockdown of YAP, SUZ12, and EZH2 compared to nonsense siRNA treatment in 
HepG2 cells. 
Interestingly, this comparison revealed LXR/RXR-activation as highest induced pathway after all 
types of inhibitions (p = 3x10-5 to 3x10-10), which has many similarities to the FXR/RXR pathway. 
The heatmap in Figure 23B shows the genes associated with LXR/RXR activation after YAP, 
SUZ12, or EZH2 silencing and their expression values normalized to the NTC control. To confirm 
whether the regulated genes were affected by the PRC2 upstream regulator YAP, real-time PCR 
was performed after YAP and TAZ-inhibition in HepG2 cells for 48 h analyzing some LXR/RXR 
associated genes (84). 
The mRNA expression data revealed that ATP binding cassette subfamily A member 1 (ABCA1) 
and apolipoprotein C3 (APOC3) were indeed induced as predicted by the expression profiling 
data (Figure 23C).The results for ABCA1 and APOE were inconsistent since only one siRNA 
combination for YAP and TAZ affected these genes (Figure 23C). These results indicate that YAP 
could negatively regulate the transcription of a target gene subgroup probably through the 
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induction of PRC2 components, which silence gene transcription via histone methylation. First 
bioinformatic analysis of high-throughput data revealed that the LXR/RXR activation has been 
revealed as a downstream effector of YAP reduction. This suggests that YAP-positive tumors 
inactivate the LXR/RXR-pathway via PRC2 induction, preventing apoptosis in tumor cells (85). 
 
Figure 23: IPA analysis after transcriptome analysis. 
(A) Heatmap of IPA comparison analysis showing z-scores (max. = 3,74; min. = -3,32) of top 20 canonical pathways activated and 
deactivated within analyzed transcriptomic data. (B) Expression profiling of LXR/RXR activation-associated genes after RNAi 
knockdown of YAP, SUZ12, and EZH2 normalized to nonsense siRNA treatment in HepG2 cells. (C) Transient transfection of each 
two YAP and TAZ-specific siRNAs increased expression levels of some LXR/RXR activation-associated genes, as illustrated by real-
time PCR. The mean±SD of three independent experiments in HepG2 cells is shown. Untreated (Ø) and nonsense siRNA (NTC) 
transfected cells served as controls. Data were normalized to NTC controls. 
5.3.5 YAP Expression Correlates to SUZ12 and EZH2 Expression in Human HCC 
Given that YAP positively correlates with PRC2 component expression in vitro and in vivo and 
that the YAP-associated transcription factor TEAD4 directly bound to the promoter regions of 
EZH2, RBBP7 and SUZ12, the next aim was to confirm this association in human HCC tissues. 
Therefore, mRNA expression data of 242 HCC patients (cohort 1) (72) and 370 liver cancer 
patients (cohort 2) (27) was analyzed. Figure 24 shows the comparison of mRNA expression 
levels of liver tumors compared to surrounding tissue, illustrating a significant overexpression of 
the PRC2 components EED, EZH2, RBBP4, RBBP7, and SUZ12 in HCC. No such induction was 
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detectable for EZH1. 
 
Figure 24: Elevated expression of PRC2 components in human HCCs. 
EZH2, RBBP7, and SUZ12 mRNA is overexpressed  in HCC samples compared to surrounding tissue in a cohort of 242 liver cancer 
patients (cohort 1). (*** p < 0.001)  
 
Figure 25: Elevated expression of PRC2 components correlate with poor prognosis in HCC patients. 
Kaplan-Meier analysis of EED, EZH1, EZH2, RBBP4, RBBP7, and SUZ12 in cohort 1 with blue indicating high and red low 
expression levels. High transcript levels of EZH2 and SUZ12 significantly correlate with a worse survival probability (Wilcoxon-
test). (* p < 0.05) 
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For Kaplan-Meier analysis, patients were divided into two groups with high and low transkript 
expression of the respective PRC2 complex gene (threshold: median) (Figure 25). HCC patients 
with high EZH2, SUZ12, and EED mRNA expression tend to have shorter overall survival. Most 
PRC2 core components had no statistical impact on patient survival in the analyzed data set. 
Because only elevated SUZ12 and EZH2 levels associated significantly with patient prognosis, all 
further analysis on human samples focused on either EZH2 or SUZ12 or both. 
Table 35: Elevated expression of EZH2 correlate with clinicopathological features. 
EZH2 was used to divide patients into groups with high, medium and low expression, using mRNA expression data from 
cohort 2. Additionally, patients were divided into groups for each feature, followed by the quantification of the number of 
patients in each group. The median value was used to assign for the analysis of age. The numbers of patients with the respective 
clinicopathological feature are listed in the table together with the p-value of the statistical test (Chi-squared test). n.s.=not 
significant  
 
 
In the next step, the clinicopathological features of cohort 2 were compared with EZH2 
expression, which was consistently regulated by YAP in all previous in vitro and in vivo 
experiments. Table 35 shows the contingency tables, displaying the interrelation between EZH2 
expression [high (34%), medium (33%) and low (33%)] and patient characteristics such as age 
and tumor grading. This analysis revealed that Asian patients tended to enrich in clusters with 
higher EZH2 expression, while Caucasian patients tended to have lower EZH2 levels. The 
development of well-differentiated tumors (G1/G2) correlated with low EZH2 abundance. 
Patients with increased inflammation or vascular invasion of tumor tissue were evenly 
distributed within the EZH2 clusters. However, the patient age of 61 years and older at diagnosis 
was associated with lower EZH2 expression, whereas younger patients significantly expressed 
higher EZH2 levels. Gender, body mass index and family history didn't show any association with 
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EZH2 expression levels. 
Together, these findings show that PRC2 is overexpressed in human HCC and that the 
expression of some PRC2 complex proteins such as EZH2 and SUZ12 significantly correlates with 
poor clinical outcome of HCC patients. 
5.3.6 YAP Expression Correlates to PRC2 Expression in Human HCC 
Finally, the protein abundance and its correlation with YAP levels was analyzed using an HCC-
TMA (105 HCCs and 7 normal liver tissues). Figure 26 shows exemplary YAP-positive and YAP-
negative IHC stains as well as corresponding EZH2 and SUZ12 stains. 
 
Figure 26: YAP expression correlates with EZH2 and SUZ12 expression in HCC patients. 
Exemplary immunohistochemical stains of YAP positive and negative human HCC tissue stained for YAP, EZH2 and SUZ12. 
In accordance with the Kaplan-Meier analysis and the correlation data of EZH2 mRNA 
expression with tumor grading, the TMA evaluation showed a significant correlation of YAP, 
SUZ12 and EZH2 protein expression with tumor grading (Figure 27; Table 36). The systematic 
evaluation of all TMAs also revealed a significant correlation of nuclear YAP expression with the 
analyzed PRC2 components SUZ12 and EZH2 as illustrated in Table 36.  
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In summary, these findings emphasize that PRC2 components EZH2 and SUZ12 strongly 
correlate with nuclear YAP expression in human HCC 
 
Figure 27: YAP, EZH2, and SUZ12 expression correlate with tumor grading in HCC patients. 
TMA evaluation shows a significant correlation between YAP, EZH2 and SUZ12 levels with tumor gradings (G1-G4) as illustrated 
by the bar graph. G0 = healthy liver. 
 
Table 36: YAP and Ki67 expression correlate with EZH2 and SUZ12 levels and histological grading in HCC patients. 
Spearman correlation analysis of evaluated TMAs illustrates a significant correlation between YAP and Ki67 with EZH2 and 
SUZ12 levels and tumor gradings (G). (* p < 0.5; ** p < 0.01). 
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6 Discussion 
Hippo pathway and its effectors are frequently deregulated in the context of liver cancer 
development. This study identified novel target gene families with the potential to mediate the 
oncogenic properties of YAP and TAZ (Figure 28). 
 
Figure 28: Overview depicting the mechanism of YAP depended MCM helicase and PRC2 induction. 
Turning off the Hippo pathway results in nuclear YAP and TAZ accumulation inducing the transcription of target genes (MCM2-7, 
EED, EZH2, SUZ12 and RBBP7). Increased amount of MCM proteins (yellow circles) leads to elevated MCM helicase abundance 
and increased proliferation. Target gene transcription was repressed upon increased PRC2 mediated H3K27me3. 
In this study, it could be determined that, YAP and TAZ induce the transcription of MCM 
helicase, which is necessary for DNA replication. The overexpression of MCM helicase 
constituents has also been observed in human HCC tumor tissue and correlates with poor 
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clinical outcome of HCC patients. Furthermore, this study provides first evidence of YAP induced 
gene silencing by transcriptional regulation of PRC2 components, a functionally related group of 
proteins involved in epigenetic silencing of gene transcription. Taken together these data 
pinpoint novel YAP/TAZ target genes induced in human HCCs, which might represent interesting 
therapeutic target structures for the treatment of YAP-driven liver tumors.  
6.1 MCM Helicase  
6.1.1 Dysregulation of MCM Helicase Subunits in Hepatocarcinogenesis 
overexpressed during carcinogenesis in a Hippo pathway-dependent manner. In this study, 
elevated levels of MCM helicase subunits have been identified as novel YAP/TAZ-regulated gene 
family in hepatocarcinogenesis. Moreover, increased MCM expression was linked with poor 
clinical outcome of HCC patients, which corresponds with the pro-tumorigenic properties of YAP 
and TAZ in tumorigenesis.  
The naming minichromosome maintenance (MCM) of the MCM genes originates from a 
mutation screen performed in budding yeast (86). Based on these results, the authors 
hypothesized, that only a small number of proteins is responsible for the initiation of a large 
number of replication origins (86). Amongst the identified proteins, six factors share a high 
degree of structural and functional similarities and were called the MCM protein family or MCM 
helicase (MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7). Genes coding for MCMs are 
located on different chromosomes and share structural similarities with regard to the so-called 
MCM-box and a zink finger motif, presented in Figure 29 (87). Additionally to the shared 
functional characteristics, the human MCM proteins share 31-38% identical amino acids with 
each other. 
 
Figure 29: MCM helicase sequence homology. 
(A) Scheme showing the conserved domain structure of MCM proteins. (B) To obtain shared motifs among the human MCM 
helicase, protein sequences were aligned with COBALT-software. Residues conserved among the six sequences in the alignment 
are shaded in red. 
Each MCM-box consists of three functional amino acid sequences. The Walker A and B ATPase 
motifs, which are responsible for the binding and hydrolysis of ATP, and the arginin finger motif, 
binding the γ-phosphate and facilitates its cleavage (87). The energy of ATP hydrolysis is used to 
separate the strands of the DNA double helix. Since the discovery of MCM helicase in the 
context of impaired proliferation, several attempts have been made to analyze the role of these 
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proteins in carcinogenesis. Freeman et al. performed immunohistochemical analysis to evaluate 
the expression of MCM2, MCM5, and Ki67 in 210 healthy and matched tumor tissues including 
lung, colon, skin and bladder tissues (88). In tumor samples, the authors detected a high 
correlation between MCM expression and Ki67 levels, linking MCM expression to the 
proliferative activity of tumor cells in different cancer types. Moreover, the amount of MCM2 
and MCM5 positive nuclei gradually increased with tumor dedifferentiation, with approximately 
20% positive nuclei in normal tissue to 100% in poorly differentiated tumors (88). 
Interestingly, the study presented here does not only show an elevated abundance of MCM2, 
MCM6, and MCM7 proteins in HCC tissues, but also revealed a statistical association between 
all analyzed MCM helicase members with increasing tumor grade/dedifferentiation. 
Additionally, a highly significant correlation between the proliferation marker Ki67 and MCM 
helicase protein abundance in HCC tumor tissue was confirmed. For hepatocarcinogenesis, the 
present study confirmed similar reports with immunohistochemical analysis revealing elevated 
expression of MCM2 (89), MCM6 (90) and MCM7 (91) in HCCs compared to normal liver tissues.  
Furthermore, elevated mRNA expression levels of different MCM genes in human HCCs 
compared to normal and cirrhotic livers have been detected in this study. The analysis of two 
published HCC cohorts (27, 72) showed high mRNA expression of each MCM family member 
correlating with poor overall and disease-free survival. Moreover, an MCM score, calculated to 
rank the MCM helicase expression within each HCC sample, could link elevated MCM expression 
to several clinicopathological features and etiologic factors as race, age and tumor progression. 
These results are in line with the IHC analysis of Liu et al. (90) and the recently published 
analysis of these cohorts by Liao et al. (92). 
In summary, the results from this study and published literature illustrate that individual MCM 
proteins represent reliable markers of physiological and pathologicall hepatocyte and HCC cell 
proliferation. Moreover, high mRNA expression of MCM helicase in HCC patients is a useful 
marker to predict a worse clinical outcome. 
6.1.2 MCM Helicase is a Downstream Target of YAP, TAZ, and TEAD4 
All ten known human MCM proteins are associated with cell cycle progression. Six of them, 
MCM2-7, form a ring-shaped hexameric complex during the G1 cell cycle phase, named the 
MCM helicase (78). As discussed in chapter 6.1.1, MCM helicase overexpression correlates with 
proliferation and tumor progression in HCC. However, the mechanistic reason for increased 
MCM expression in HCC cells is poorly understood. 
Chromosomal alterations of MCM genes in the context of cancer progression have been rarely 
described in different tumor types. For example, array comparative genomic hybridization 
(aCGH) of 23 non-small cell lung cancer tumors revealed chromosomal amplification of MCM2 
and MCM6 (93). Additionally genome-wide copy number and microarray mRNA expression 
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analysis of 25 paired healthy/tumorous gastric tissues showed amplification of the MCM3 and 
MCM4 genes (94). Furthermore, previous studies demonstrated that a chromosomal 
amplification of the chromosomal region 7q21‐22 frequently occurred in gastric cancer, 
including the MCM7 gene (95). Interestingly, this report also showed that mir-25 can suppress 
the tumor suppressor p53, thereby providing an additional oncogenic stimulus for hepatocytes 
(95). MCM proteins are evolutionary highly conserved throughout eukaryotes, but the individual 
genes are located on different chromosomal regions suggesting that each single MCM protein 
may have specific roles in DNA replication (87, 96). Nevertheless, publications only report the 
amplification of individual MCM genes so far but not simultaneous genomic gains and so far no 
reports focusing on the situation of MCMs in liver cancer have been published. This indicates 
that other molecular mechanisms might be responsible for the cooperative overexpression of 
MCM observed in HCC cells. 
In order to ensure proper DNA replication, all six MCM proteins must be present at specific cell 
cycle phases. This suggests that overexpression of MCM helicase constituents has to be 
collectively induced by higher level mechanisms such as common transcriptional regulation. For 
example, Petrocca et al. analyzed gastric cancer cell lines and detected the expression of MCM7 
and a cluster of microRNAs regulated by the cell-cycle associated transcription factor E2F 
transcription factor 1 (E2F1) (97). Additionally, E2F1 has also been shown to induce MCM5 and 
MCM6 transcription in rat embryonic fibroblast REF52 cells (98). Another member of the E2F 
family, E2F2, was identified by ChIP analysis, to interact with cAMP responsive element binding 
protein (CREB) and to cooperatively repress MCM5 transcription (99). It is therefore tempting to 
speculate that transcriptional regulation is the most important mechanism for the cooperative 
overexpression of all MCM family members. This is supported by results from our laboratory, 
illustrating that YAP and TAZ together with the transcription factor FOXM1 induce the 
expression of the so-called chromosome instability (CIN) gene signature in liver cancer cells with 
MCM2 and MCM7 being part of CIN70 (38). 
Inhibition of the Hippo pathway or YAP activation is known to induce proliferation, as was 
shown in different cell lines and transgenic mouse models (61, 100). Moreover, expression data 
analysis showed repression of cell cycle-associated genes upon YAP inhibition (38, 101). In line 
with published data, we found all individual MCMs being downregulated upon YAP inhibition in 
liver cancer cells (5.2.1). Furthermore, we determined that combined YAP and TAZ reduction led 
to an even stronger decrease of all MCM helicase components. The direct physical relevance of 
YAP, TAZ, and TEAD4 was proven by ChIP and reporter gene assays for most of the MCM 
helicase promoters. Nevertheless, further experiments need to be conducted to substantiate 
that the Hippo pathway is one of the major drivers for the regulation of MCM helicase 
expression. Moreover, it would be interesting to investigate if and how YAP, TAZ, and TEAD4 
physically interact in the transcriptional regulation of target genes.  
Discussion 
80 
 
Together these results demonstrate that the Hippo/YAP/TAZ pathway is involved in the 
regulation of the complete MCM protein family, which might be critical for tumor cells to 
facilitate fast and efficient DNA replication and cell proliferation. 
6.1.3 YAP Supports Proliferation via the MCM Helicase 
Proliferation is characterized by increased cell growth as well as fast and frequent mitosis. Cell 
cycle progression is tightly regulated by hormones and growth factors modifying the expression 
and activation of cyclins, CDKs, and replisome proteins. Indeed, the Hippo/YAP/TAZ pathway has 
been frequently associated with the regulation of proliferation and cell cycle progression. 
Recently, it has been shown that YAP regulates the expression of the CIN gene signature 
involving several cell cycle-associated genes including MCM2 and MCM7 (38). To ensure proper 
proliferation, functionally related groups of genes have to be regulated and coordinated. 
In order to ensure error-free DNA duplication, thousands of DNA replication origins have to fire 
simultaneously during S-Phase. Therefore all replication origins are already licensed in the G1 
cell cycle phase which allows their immediate response to activating stimuli. Origin licensing is 
the initial step in DNA duplication where the pre-replicative complex (pre-RC) is loaded on the 
DNA. The pre-RC forms when the origin recognition complex subunit (ORC) 1-6, chromatin 
licensing and DNA replication factor 1 (CDT1), cell division cycle (CDC) 6, and the MCM helicase, 
duplet’s, are loaded onto double-stranded DNA (102). 
G1/S cell cycle transition is eventually initialized by the assembly of the so-called CMG-helicase, 
CDC45, MCM2-7, and GINS complex (GINS complex subunit 1-4), and phosphorylation of MCMs 
by activated cyclin dependent kinases (CDK) and Dbf4-dependent kinase (DDK). About 50,000 to 
100,000 activated replication origins per cell have been identified in different cell lines (103). 
Interestingly, the present study stated on one hand that RNAi-mediated inhibition of individual 
MCM proteins had no effect on cell viability and on the other hand that the disruption of MCM2 
gene using CRISPR/Cas9 reduced proliferation. This might be explained by the excess of origins 
licensed during the G1 cell cycle phase. The licensed but not initially firing origins are called 
‘silent’ or ‘dormant origins’ and get activated upon replication fork stalling and improper DNA 
replication, serving as back-up origins to ensure proper DNA duplication. This shows that much 
more pre-RC proteins exist than needed during cell cycle progression. In order to prevent re-
replication when two replication forks meet, the activity of CMG-helicases has to be stopped. 
Amongst other mechanisms, Moreno et al. reported polyubiquitinylation of MCM7 followed by 
degradation during replication fork termination in xenopus laevis egg extract (104). Upon S/G2 
cell cycle transition, MCMs get modified and thereby subsequently degraded, enforcing new 
MCM transcription and nuclear translocation (105). 
In this study it could be determined that YAP can induce cell proliferation partly through the 
regulation of MCM expression. YAP and MCM2-7 inhibition in liver cancer cells led to reduced 
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proliferation rate as demonstrated by diminished BrdU incorporation (Figure 12). The anti-
proliferative effects were comparable between both approaches, even though MCM helicase 
reduction upon YAP inhibition was less effective than targeted MCM2-7 inhibition. This suggests 
that YAP partly mediates its functional properties regarding replication and proliferation 
through the MCM helicase. However, it is likely that also other cell cycle-associated genes are 
critical downstream effectors of YAP. Indeed, a recent publication showed the regulation of cell 
cycle-associated genes as cyclin B1, CDC2, and CDC45 by YAP (38). Still, it remains to be 
elucidated, whether all of these genes are direct YAP target genes and if their upregulation can 
mimic YAP-mediated proliferation.  
In summary, the results complement previous studies, both demonstrating that deregulation of 
YAP expression has direct effects on cell proliferation partly mediated by the transcriptional 
regulation of MCMs. It is tempting to speculate that MCM helicase presence and activity could 
represent a potential marker for YAP-dependent HCC proliferation or a therapeutic target 
structure. 
6.2 PRC2 
6.2.1 Dysregulation of PRC2 in HCC Development 
Considering the hepatocarcinogenesis process, epigenetic changes have been frequently 
observed in chronic liver damage caused by different etiologies (106). Epigenetics is currently 
defined as ‘the study of changes in gene function that are mitotically and/or meiotically 
heritable and that do not entail a change in DNA sequence’ (107). Thus, epigenetic imprints are 
passed to daughter cells during cell division, which is not only important for embryonic 
development but also for carcinogenesis in case of dysregulation (108). 
The most common cellular tools to adjust epigenetic-dependent gene expression are 
posttranslational modifications of histones or DNA bases (109). In this study on 
hepatocarcinogenesis, YAP/TAZ-dependent expression changes of several histone modifying 
proteins have been observed. Covalent N-terminal modifications of histones are introduced and 
removed by a variety of enzymes and protein complexes, with direct impact on gene 
transcription. The protein complex found to be regulated by YAP and TAZ in this study is a 
member of the Polycomb group (PcG), known to repress target gene expression by histone 
methylation. PcG proteins have been first identified in Drosophila melanogaster, regulating the 
expression of HOX genes and ensuring the proper segment identity during embryonal 
development (110). In total, three complex families have been identified containing PcG 
proteins, namely PhoRC, polycomb repressive complex 1 and 2. 
All identified PcG proteins deregulated upon YAP inhibition in this study are members of PRC2, 
which is composed of the core components EZH1/2, SUZ12, RBBP4/7, EED and several variable 
proteins (111). The relevance of PRC2 in embryonic development has been proven by different 
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transgenic mouse models. Since EZH1 is ubiquitously and continuously expressed and EZH2 is 
highly associated with cell proliferation in wildtype mice, the major focus of this study lies on 
EZH2 (112). Mouse embryos lacking SUZ12, EED or EZH2 showed developmental and 
proliferative defects and were not viable (79, 113). Interestingly, even though the proteins 
SUZ12 (79) and EED (114) are essential to PRC2 function, protein expression data in human 
cancer tissue is scarce. In contrast, the overexpression of the catalytic subunit EZH2 in human 
cancers has frequently been described, as is the case for breast cancer (115), prostate cancer 
(116) and lymphomas (117). In this study, an overexpression of SUZ12 and EZH2 in human HCC 
samples could be demonstrated, which is supported by findings of Au SL et al. in 2012 (118). 
Additionally, this project showed that increasing EZH2 expression correlates with poor tumor 
differentiation of HCCs, as previously shown by Sasaki et al. (119). All these data underline the 
relevance of EZH2 in carcinogenesis at least as a marker for cancer progression. Cai et al. found 
increased expression of 3meK27H3, the epigenetic mark of the PRC2 complex, in human HCC 
tissues (120). Furthermore, Xu K et al. and Kim J et al. found a PRC2-independent role of EZH2 in 
carcinogenesis, showing that EZH2 and androgen receptor (AR) cooperate in target gene 
activation (121, 122). This might explain the frequent dysregulation of EZH2 in comparison to 
other PRC2 components.  
In summary, this study illustrated an increased expression of PRC2 components, especially 
EZH2, in HCCs and a correlation with worse clinical outcome of liver cancer patients. 
6.2.2 PRC2 is a Downstream Target of YAP and TEAD4 
The Hippo pathway effector YAP is known to interact with TEAD4 in the induction of target gene 
transcription associated with cell cycle progression and induction of cell growth (34). Several 
novel YAP target genes have been identified, amongst them are genes associated with poor 
clinical outcome like MCM proteins and the PRC2 member EZH2 (38).  
It has been shown that the PRC2 complex is crucial to embryonic development and individual 
components are frequently overexpressed in different tumor entities. In line with the poor 
clinical outcome of patients with increased EZH2 expression, an imbalance in PRC2 composition 
and activity could contribute to tumor formation and progression. The relevance of PRC2 
components in carcinogenesis has been further supported by RNAi experiments, showing cell 
growth inhibition (123) and reduced cell proliferation (116) upon EZH2 withdrawal. For this 
reason, it is crucial to understand mechanisms regulating the expression of PRC2 components. 
The relevance of PRC2 components for cell growth, identified in this study as YAP-dependent, 
has been confirmed by at least two independent publications. Bracken et al. described a direct 
pRB/E2F-dependent regulation of EZH2 and EED expression during cell growth (124). They 
showed that the promoter regions of EED and EZH2 are responsive to the transcription factors 
E2F1, E2F2, and E2F3 in reporter gene assays and confirmed the physical binding of E2F3 and 
E2F4 to the EZH2 promoter by ChIP assays. Another study illustrated not only the binding of β-
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catenin to the SUZ12 promoter but also an increased binding in colon cancer compared to 
healthy colon tissue, thereby suggesting a role of PRC2 in cancer progression (125). 
Furthermore, PRC2 may provide cancer cells with a growth advantage since it is involved in 
cancer cell resistance to conventional chemotherapeutics or irradiation therapy. In this case, 
EZH2, SUZ12, and EED are actively recruited to DNA damage sites, while depletion of EZH2 leads 
to a less efficient double-strand break repair and increased sensitivity to gamma irradiation 
(126). 
The results of this study illustrate that the Hippo/YAP pathway may directly affect PRC2 activity 
via regulation of PRC2 constituent expression. Indeed, first evidence for a connection of the 
Hippo pathway with PRC2 activity in regulating target gene transcription has recently been 
reported. Wang et al. showed in breast cancer cells that YAP directly binds to EZH2 at 
promoters, thereby repressing gene expression (127). Data provided in the present study could 
not only demonstrate that YAP levels effect the expression of EZH2 and other PRC2 
components, but also a direct physical binding of YAP and TEAD4 to the promoter sites of EZH2 
and SUZ12. Together, these data illustrate the existence of multiple regulatory mechanisms 
connecting the Hippo pathway with PRC2 complex activity. Irrespective of the mechanism, the 
Hippo/YAP axis seems to be the superior regulator controlling PRC2 abundance and activity. 
6.2.3 YAP Represses Target Genes Using PRC2 
It has been shown, that YAP and TEAD4 can repress gene expression, thereby inducing cell 
survival (128). Even though different mechanisms regulating YAP mediated target gene 
induction are known, the repressed genes and the underlying mechanism remain poorly 
studied. This study identified members of the transcriptional repression complex PRC2 as a 
direct YAP and TEAD4 target gene, which might represent an additional molecular mechanism of 
how the Hippo pathway could diminishes gene expression. 
Epigenetic regulation of gene expression is involved in different physiological and pathological 
processes such as stem cell differentiation and tumorigenesis (129, 130). Among different 
epigenetic marks, covalent histone modifications were found to modify chromatin density and 
the accessibility of DNA by other proteins, which was called the histone code hypothesis (131). 
N-terminal histone modifications, including methylation, acetylation, ADP ribosylation, 
ubiquitination, citrullination, and phosphorylation, are introduced and removed by a variety of 
enzymes and protein complexes (132). Especially, acetylation of histones is usually associated 
with transcriptional activation (e.g. H3K9, H3K14, H3K18, H3K23, H4K5, H4K8, H4K12, and 
H4K16), while histone methylation, depending on location and extent of the modification, can 
inhibit (H3K9, H3K27, and H4K20) as well as activate (H3K4, H3K36, and H3K79) gene 
transcription (109).  
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The repressive mark H3K27me3 is introduced by the complex PRC2 leading to chromosomal 
condensation and eventually HOX repression (133). Vice versa, RNAi-mediated silencing of 
EZH2, EED, or SUZ12 de-repressed different target genes in human embryonic fibroblasts (134). 
The present study delineates that YAP inhibition results in increased target gene expression, as 
the ABC transporter components ABCA1 and ABCB1, while reducing the transcription of PRC2 
components. A recently identified target gene of PRC2 is EPCAM, which is re-expressed in HBV-
positive cells upon SUZ12 knockdown and represents a marker for hepatic cancer stem cells 
(135). Additionally, the present study illustrates a YAP-dependent EZH2 and SUZ12 transcription, 
which led to the assumption that YAP overexpression might represses EPCAM expression via 
PRC2 induction. Another possibility might be a non-transcriptional interaction between YAP and 
PRC2, since such a mechanism has been described in breast cancer cells (127).  
This study shows direct binding of TEAD4 to EZH2, RBBP7 and SUZ12 promoter regions, 
indicating that the Hippo pathway regulates PRC2 abundance and activity to repress target gene 
expression. Indeed, the microarray data show that 19% of the significantly upregulated genes 
after YAP inhibition are identical to genes effected by SUZ12 and EZH2 inhibition. This indicates 
that besides direct transcriptional regulation, YAP could indirectly repress the expression of 
target genes by highjacking the PRC2 complex. This is in line with data from Kim and colleagues, 
who identified target genes repressed by YAP and TEAD4, which are not affected by EZH2 
depletion (128). These data underline the importance for the identification of direct and indirect 
YAP target genes in order to develop pharmaceutical approaches to repress oncogenic YAP 
activity without interfering with regenerative capabilities. 
Altogether these results illustrate that YAP can not only induce target gene expression but also 
repress gene transcription. In the light of published data, the results presented here indicate 
that YAP represses PRC2 target genes, which might lead to the identification of novel Hippo 
pathway regulatory feedback loops. 
6.3 Therapeutic approaches 
HCC exhibits a poor survival rate and few therapeutic options, as described in 1.1.2. Since HCCs 
have different molecular features (1.1.3) and current systemic treatment options only include 
multi-kinase inhibitors and tyrosin kinase inhibitors, research focuses on identifying more 
specific approaches. Given that the Hippo pathway is important for carcinogenesis (1.2.2), first 
perturbation approaches targeting this pathway have been developed. Verteporfin, which is 
also used as pharmacological inhibitor in this study, is known to disrupt the YAP-TEAD 
interaction leading to the proteasomal degradation of YAP and TEAD (37). Indeed, Verteporfin 
treatment of liver cancer cells in this study showed a dose-dependent decrease of YAP-target 
gene expression, which is in line with previous publications (38, 136). However, the total 
blockage of the Hippo pathway might also hava adverse effects, since it is required for liver 
regeneration as illustrated by partial hepatectomy in adult mice, where the omitted YAP/TAZ-
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mediated effects could not be compensated by other pro-proliferative pathways (137). These 
data suggests that a more specific approach is needed to target downstream effects of YAP and 
TAZ with the aim to find druggable oncogenic targets without preventing liver regeneration 
upon treatment.  
As discussed in section 6.1.2, the MCM helicase was identified as a direct YAP and TAZ target 
gene, which is directly involved in cell proliferation. Already during physiological cell 
proliferation, an excess amount of MCMs compared to the theoretically minimal requirement 
for sufficient DNA duplication can be detected (138). Even more, MCM proteins are detectable 
in precancerous lesions and cancer tissue, as shown in sections 5.2.2 and 5.2.5. These facts 
imply that a change in cell viability upon suboptimal MCM reduction could not be expected, 
which was acertained in Figure 10. Theoretically, the therapeutic abolishment of MCMs would 
result in a replication block leading to senescence or apoptosis. Initial CRISPR/Cas9 experiments 
presented in this study show the expected reduction in cell proliferation (Figure 11), which 
would be a valuable approach for cancer treatment of HCC patients, though it might be fatal for 
the surrounding regenerative and chronically damaged liver. Therefore, the MCM helicase does 
not appear to be a suitable target for drug development, but MCMs could serve as proliferation 
and prognostic marker as discussed in section 6.1.1. 
Another YAP target identified in this study is PRC2, a complex responsible for epigenetic 
repression of gene transcription (6.2.3). Due to the frequent deregulations of PRC2 components 
in different cancers, several pharmaceutical approaches to inhibit the function of EZH2, the key 
enzyme of the complex, have been developed (139). First approaches to inhibit PRC2 effects in 
breast cancer were made using S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin 
A (DZNep), which efficiently induced apoptotic cell death in cancer cells but not in normal cells 
(140). Several EZH2 inhibitors are currently in clinical trials (141), with Tazemetostat presenting 
a highly potent and selective inhibitor directly binding EZH2 (83). In the course of this study, it 
could be shown that Tazemetostat could efficiently reduce H3K27me3 in different liver cancer 
cell lines, supporting the results that led to the initiation of a clinical trial. First recent data show 
a favorable safety profile and antitumor activity in advanced solid tumors and lymphomas (142). 
In addition to targeting the enzymatic activity of PRC2, the disruption of the complex was 
explored by targeting EED. The H3K27me3-binding function of EED is blocked by newly 
developed small molecules, like EED226, which allosterically inhibit EZH2 enzymatic activity and 
disrupt the complex (143, 144). A comparable inhibitor, A-395, demonstrates even superior 
effects on tumor growth inhibition in vivo relative to the mentioned EZH2 inhibitors (145). The 
recent increase in availability of PRC2-inhibiting drugs provides novel interesting tool for further 
investigation to disrupt oncogenic PRC2/YAP feedback loops. 
In summary, the Hippo pathway is a major regulator of cell proliferation, equally important for 
liver regeneration as well as cancer progression. Therefore, downstream effectors of YAP and 
Discussion 
86 
 
TAZ had to be evaluated for target potential. Especially the PRC2 components EZH2, EED and 
SUZ12, target genes identified in this study proved to be promising targets for further 
evaluation.  
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10 Appendix 
Table 37: 66 genes significantly upregulated upon SUZ12, EZH2 and YAP inhibition. 
Gene 
Symbol 
Gene name CHR REFSEQ-ID 
A1CF APOBEC1 complementation factor 10 NM_001198818 
AHSG alpha 2-HS glycoprotein 3 NM_001354571 
ALB albumin 4 NM_000477 
ALCAM activated leukocyte cell adhesion molecule 3 NM_001243280 
ALDH2 aldehyde dehydrogenase 2 family 12 NM_000690 
AMBP alpha-1-microglobulin/bikunin precursor 9 NM_001633 
APOH apolipoprotein H 17 NM_000042 
ATF2 activating transcription factor 2 2 NM_001256090 
ATP11C ATPase phospholipid transporting 11C X NM_001010986 
ATP7B ATPase copper transporting beta 13 NM_000053 
ATRN attractin 20 NM_001207047 
C11orf54 chromosome 11 open reading frame 54 11 NM_001286067 
C1S complement C1s 12 NM_001346850 
C2 complement C2 6 NM_000063 
C5 complement C5 9 NM_001317163 
C6orf62 chromosome 6 open reading frame 62 6 NM_030939 
CASK calcium/calmodulin dependent serine prot X NM_001126054 
CLOCK clock circadian regulator 4 NM_001267843 
CPQ carboxypeptidase Q 8 NM_016134 
CYP27A1 cytochrome P450 family 27 subfamily A member 1 2 NM_000784 
DHRS3 dehydrogenase/reductase 3 1 NM_001319225 
EML6 echinoderm microtubule associated protein 6 2 NM_001039753 
EMSY EMSY, BRCA2 interacting transcriptional 11 NM_001300942 
ERAP1 endoplasmic reticulum aminopeptidase 1 5 NM_001040458 
F10 coagulation factor X 13 NM_000504 
F5 coagulation factor V 1 NM_000130 
FAM3B family with sequence similarity 3 member B 21 NM_058186 
FST follistatin 5 NM_006350 
GPR160 G protein-coupled receptor 160 3 NM_014373 
IGSF1 immunoglobulin superfamily member 1 X NM_001170961 
INPP5A inositol polyphosphate-5-phosphatase A 10 NM_001321042 
ITIH2 inter-alpha-trypsin inhibitor heavy chai 10 NM_002216 
KANK4 KN motif and ankyrin repeat domains 4 1 NM_001320269 
LRP1 LDL receptor related protein 1 12 NM_002332 
Appendix 
99 
 
MAPK8 mitogen-activated protein kinase 8 10 NM_001278547 
MGC12916 uncharacterized protein MGC12916 17 NM_032729 
MTTP microsomal triglyceride transfer protein 4 NM_000253 
NDST1 N-deacetylase and N-sulfotransferase 1 5 NM_001301063 
NFE2L2 nuclear factor, erythroid 2 like 2 2 NM_001145412 
ORM1 orosomucoid 1 9 NM_000607 
ORM2 orosomucoid 2 9 NM_000608 
PALMD palmdelphin 1 NM_017734 
PIP4K2B phosphatidylinositol-5-phosphate 4-kinase type 2 beta 17 NM_003559 
PTPRF protein tyrosine phosphatase receptor type 1 NM_001329137 
RALGAPA2 Ral GTPase activating protein catalytic 20 NM_020343 
RAPGEF1 Rap guanine nucleotide exchange factor 1 9 NM_001304275 
RMND5A required for meiotic nuclear division 5 2 NM_022780 
ROBO1 roundabout guidance receptor 1 3 NM_001145845 
SCARNA9 small Cajal body-specific RNA 9 11 NR_002569 
SEC11C SEC11 homolog C, signal peptidase complex subunit 18 NM_001307941 
SERPINA4 serpin family A member 4 14 NM_001289032 
SERPIND1 serpin family D member 1 22 NM_000185 
SERPINF1 serpin family F member 1 17 NM_001329903 
SERPINI1 serpin family I member 1 3 NM_001122752 
SLC5A9 solute carrier family 5 member 9 1 NM_001011547 
SMLR1 small leucine rich protein 1 6 NM_001195597 
SNORA47 small nucleolar RNA, H/ACA box 47 5 NR_003014 
SNORA49 small nucleolar RNA, H/ACA box 49 12 NR_002979 
STK38L serine/threonine kinase 38 like 12 NM_015000 
TAF11 TATA-box binding protein associated fact 6 NM_001270488 
TEX2 testis expressed 2 17 NM_001288732 
TF transferrin 3 NM_001063 
TTC3 tetratricopeptide repeat domain 3 21 NM_001001894 
VEGFA vascular endothelial growth factor A 6 NM_001025366 
WASF3 WAS protein family member 3 13 NM_001291965 
ZNF217 zinc finger protein 217 20 NM_006526 
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Table 38: Fold-change and adjusted p-values (FDP) of 66 significantly upregulated genes. 
 
#1 EZH2 #2 EZH2 #1 SUZ12 #2 SUZ12 #1 YAP #2 YAP 
Gene 
Symbol 
fold-
change 
FDR 
fold-
change 
FDR 
fold-
change 
FDR 
fold-
change 
FDR 
fold-
change 
FDR 
fold-
change 
FDR 
A1CF 1,05 0,000 1,12 0,000 1,08 0,000 1,06 0,000 1,06 0,000 1,17 0,000 
AHSG 1,01 0,031 1,05 0,000 1,03 0,000 1,03 0,000 1,03 0,000 1,06 0,000 
ALB 1,05 0,000 1,08 0,000 1,11 0,000 1,03 0,000 1,04 0,000 1,08 0,000 
ALCAM 1,06 0,000 1,09 0,000 1,11 0,000 1,08 0,000 1,07 0,000 1,14 0,000 
ALDH2 1,02 0,037 1,10 0,000 1,07 0,000 1,04 0,000 1,02 0,009 1,03 0,001 
AMBP 1,06 0,000 1,03 0,001 1,07 0,000 1,03 0,002 1,02 0,045 1,09 0,000 
APOH 1,05 0,000 1,06 0,000 1,04 0,000 1,04 0,000 1,03 0,000 1,07 0,000 
ATF2 1,05 0,000 1,05 0,000 1,05 0,000 1,03 0,001 1,03 0,003 1,06 0,000 
ATP11C 1,03 0,019 1,04 0,002 1,07 0,000 1,04 0,002 1,06 0,000 1,04 0,003 
ATP7B 1,02 0,027 1,08 0,000 1,03 0,002 1,04 0,000 1,02 0,007 1,07 0,000 
ATRN 1,03 0,000 1,02 0,002 1,03 0,001 1,03 0,002 1,02 0,018 1,04 0,000 
C11orf54 1,07 0,000 1,08 0,000 1,08 0,000 1,04 0,018 1,06 0,001 1,08 0,000 
C1S 1,07 0,000 1,30 0,000 1,39 0,000 1,12 0,000 1,04 0,015 1,10 0,000 
C2 1,05 0,000 1,12 0,000 1,10 0,000 1,06 0,000 1,04 0,001 1,10 0,000 
C5 1,15 0,000 1,09 0,000 1,19 0,000 1,08 0,000 1,07 0,001 1,10 0,000 
C6orf62 1,05 0,000 1,04 0,000 1,05 0,000 1,06 0,000 1,04 0,000 1,02 0,002 
CASK 1,05 0,000 1,05 0,000 1,04 0,000 1,10 0,000 1,04 0,001 1,05 0,000 
CLOCK 1,02 0,007 1,04 0,000 1,06 0,000 1,02 0,010 1,05 0,000 1,02 0,012 
CPQ 1,02 0,029 1,05 0,000 1,05 0,000 1,03 0,002 1,02 0,029 1,05 0,000 
CYP27A1 1,04 0,002 1,10 0,000 1,11 0,000 1,04 0,001 1,05 0,000 1,10 0,000 
DHRS3 1,04 0,000 1,03 0,008 1,08 0,000 1,04 0,001 1,03 0,018 1,04 0,000 
EML6 1,03 0,006 1,15 0,000 1,17 0,000 1,08 0,000 1,04 0,001 1,10 0,000 
EMSY 1,06 0,000 1,04 0,016 1,07 0,000 1,05 0,001 1,04 0,002 1,05 0,001 
ERAP1 1,04 0,003 1,06 0,000 1,04 0,003 1,04 0,002 1,04 0,005 1,05 0,000 
F10 1,05 0,002 1,10 0,000 1,06 0,000 1,04 0,020 1,06 0,000 1,17 0,000 
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F5 1,04 0,001 1,07 0,000 1,04 0,001 1,04 0,000 1,02 0,034 1,13 0,000 
FAM3B 1,06 0,006 1,09 0,000 1,07 0,001 1,06 0,003 1,06 0,004 1,17 0,000 
FST 1,13 0,000 1,16 0,000 1,16 0,000 1,11 0,000 1,09 0,000 1,12 0,000 
GPR160 1,06 0,000 1,03 0,031 1,06 0,000 1,05 0,000 1,03 0,031 1,04 0,004 
IGSF1 1,13 0,000 1,17 0,000 1,18 0,000 1,12 0,000 1,09 0,000 1,26 0,000 
INPP5A 1,06 0,000 1,06 0,000 1,06 0,000 1,08 0,000 1,04 0,000 1,07 0,000 
ITIH2 1,07 0,000 1,07 0,000 1,08 0,000 1,03 0,000 1,06 0,000 1,06 0,000 
KANK4 1,06 0,000 1,16 0,000 1,05 0,001 1,06 0,000 1,04 0,008 1,08 0,000 
LRP1 1,04 0,006 1,10 0,000 1,03 0,014 1,05 0,000 1,03 0,037 1,07 0,000 
MAPK8 1,07 0,000 1,08 0,000 1,06 0,000 1,08 0,000 1,07 0,000 1,06 0,000 
MGC12916 1,06 0,001 1,11 0,000 1,09 0,000 1,09 0,000 1,08 0,000 1,05 0,002 
MTTP 1,12 0,000 1,20 0,000 1,10 0,001 1,14 0,000 1,15 0,000 1,37 0,000 
NDST1 1,05 0,000 1,05 0,000 1,03 0,002 1,02 0,008 1,04 0,000 1,04 0,000 
NFE2L2 1,04 0,000 1,06 0,000 1,03 0,000 1,02 0,018 1,02 0,019 1,04 0,000 
ORM1 1,04 0,000 1,06 0,000 1,05 0,000 1,05 0,000 1,02 0,008 1,03 0,000 
ORM2 1,06 0,000 1,07 0,000 1,07 0,000 1,07 0,000 1,04 0,000 1,06 0,000 
PALMD 1,06 0,000 1,06 0,000 1,13 0,000 1,05 0,000 1,03 0,014 1,15 0,000 
PIP4K2B 1,02 0,031 1,02 0,003 1,02 0,039 1,04 0,000 1,03 0,000 1,03 0,000 
PTPRF 1,04 0,000 1,04 0,001 1,03 0,008 1,05 0,000 1,02 0,033 1,03 0,008 
RALGAPA2 1,06 0,000 1,03 0,012 1,04 0,000 1,07 0,000 1,03 0,004 1,03 0,001 
RAPGEF1 1,02 0,022 1,04 0,000 1,04 0,000 1,05 0,000 1,03 0,005 1,04 0,000 
RMND5A 1,11 0,000 1,08 0,000 1,02 0,046 1,07 0,000 1,05 0,000 1,08 0,000 
ROBO1 1,08 0,000 1,08 0,000 1,05 0,000 1,08 0,000 1,06 0,000 1,07 0,000 
SCARNA9 1,12 0,000 1,10 0,000 1,16 0,000 1,08 0,004 1,08 0,005 1,09 0,001 
SEC11C 1,04 0,023 1,09 0,000 1,05 0,006 1,06 0,000 1,05 0,002 1,09 0,000 
SERPINA4 1,09 0,000 1,05 0,000 1,11 0,000 1,05 0,000 1,04 0,001 1,08 0,000 
SERPIND1 1,07 0,000 1,06 0,000 1,12 0,000 1,03 0,010 1,03 0,001 1,11 0,000 
SERPINF1 1,05 0,000 1,05 0,000 1,06 0,000 1,04 0,000 1,02 0,014 1,05 0,000 
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SERPINI1 1,05 0,029 1,15 0,000 1,17 0,000 1,05 0,025 1,06 0,003 1,20 0,000 
SLC5A9 1,07 0,000 1,12 0,000 1,07 0,000 1,07 0,000 1,04 0,011 1,11 0,000 
SMLR1 1,06 0,003 1,08 0,000 1,16 0,000 1,04 0,030 1,05 0,007 1,18 0,000 
SNORA47 1,06 0,000 1,06 0,001 1,07 0,000 1,04 0,010 1,03 0,032 1,06 0,000 
SNORA49 1,08 0,000 1,05 0,001 1,09 0,000 1,06 0,001 1,05 0,001 1,06 0,000 
STK38L 1,06 0,000 1,05 0,001 1,08 0,000 1,08 0,000 1,08 0,000 1,08 0,000 
TAF11 1,08 0,000 1,06 0,000 1,04 0,000 1,07 0,000 1,05 0,000 1,06 0,000 
TEX2 1,04 0,000 1,05 0,000 1,03 0,002 1,06 0,000 1,04 0,000 1,06 0,000 
TF 1,04 0,000 1,08 0,000 1,07 0,000 1,04 0,000 1,04 0,000 1,04 0,000 
TTC3 1,05 0,000 1,04 0,002 1,04 0,001 1,04 0,000 1,04 0,002 1,04 0,002 
VEGFA 1,02 0,009 1,06 0,000 1,03 0,001 1,02 0,031 1,03 0,002 1,02 0,029 
WASF3 1,07 0,000 1,05 0,000 1,03 0,015 1,05 0,000 1,03 0,012 1,04 0,000 
ZNF217 1,04 0,000 1,07 0,000 1,05 0,000 1,04 0,000 1,02 0,013 1,03 0,001 
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